<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Cardiovasc. Med.</journal-id>
<journal-title>Frontiers in Cardiovascular Medicine</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Cardiovasc. Med.</abbrev-journal-title>
<issn pub-type="epub">2297-055X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fcvm.2023.1206743</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Cardiovascular Medicine</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Particularities of coronary physiology in patients with atrial fibrillation: insights from combined pressure and flow indices measurements</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes"><name><surname>Pintea Bentea</surname><given-names>Georgiana</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="corresp" rid="cor1">&#x002A;</xref><uri xlink:href="https://loop.frontiersin.org/people/2283440/overview" /></contrib>
<contrib contrib-type="author"><name><surname>Berdaoui</surname><given-names>Brahim</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib>
<contrib contrib-type="author"><name><surname>Samyn</surname><given-names>Sophie</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib>
<contrib contrib-type="author"><name><surname>Morissens</surname><given-names>Marielle</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib>
<contrib contrib-type="author"><name><surname>van de Borne</surname><given-names>Philippe</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib>
<contrib contrib-type="author"><name><surname>Castro Rodriguez</surname><given-names>Jose</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib>
</contrib-group>
<aff id="aff1"><label><sup>1</sup></label><addr-line>Department of Cardiology</addr-line>, <institution>CHU Brugmann</institution>, <addr-line>Brussels</addr-line>, <country>Belgium</country></aff>
<aff id="aff2"><label><sup>2</sup></label><addr-line>Department of Cardiology</addr-line>, <institution>CHU Erasme</institution>, <addr-line>Brussels</addr-line>, <country>Belgium</country></aff>
<author-notes>
<fn fn-type="edited-by"><p><bold>Edited by:</bold> Yankun Yang, Capital Medical University, China</p></fn>
<fn fn-type="edited-by"><p><bold>Reviewed by:</bold> Vincenzo Sucato, University of Palermo, Italy Julian Gunn, The University of Sheffield, United Kingdom Arianna Pannunzio, Sapienza University of Rome, Italy</p></fn>
<corresp id="cor1"><label>&#x002A;</label><bold>Correspondence:</bold> Georgiana Pintea Bentea <email>georgiana.pinteabentea@chu-brugmann.be</email></corresp>
</author-notes>
<pub-date pub-type="epub"><day>14</day><month>08</month><year>2023</year></pub-date>
<pub-date pub-type="collection"><year>2023</year></pub-date>
<volume>10</volume><elocation-id>1206743</elocation-id>
<history>
<date date-type="received"><day>16</day><month>04</month><year>2023</year></date>
<date date-type="accepted"><day>31</day><month>07</month><year>2023</year></date>
</history>
<permissions>
<copyright-statement>&#x00A9; 2023 Pintea Bentea, Berdaoui, Samyn, Morissens, van de Borne and Castro Rodriguez.</copyright-statement>
<copyright-year>2023</copyright-year><copyright-holder>Pintea Bentea, Berdaoui, Samyn, Morissens, van de Borne and Castro Rodriguez</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License (CC BY)</ext-link>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p></license>
</permissions>
<abstract>
<sec><title>Background</title>
<p>Symptoms suggestive of myocardial ischemia are frequently encountered in patients with atrial fibrillation (AF) even in the absence of obstructive coronary artery disease. Nevertheless, an in-depth characterisation of coronary physiology in patients with AF is currently lacking.</p>
</sec>
<sec><title>Objectives</title>
<p>We aim to provide an insight into the characteristics of coronary physiology in AF, by performing simultaneous invasive measurements of coronary flow- and pressure- indices in a real-life population of patients with AF and indication of coronary angiography.</p>
</sec>
<sec><title>Methods</title>
<p>This is a prospective open label study including patients with permanent or persistent AF and indication of coronary angiography showing intermediate coronary stenosis requiring routine physiological assessment (<italic>n</italic>&#x2009;&#x003D;&#x2009;18 vessels from 14 patients). We measured FFR (fractional flow reserve), and Doppler-derived coronary flow indices, including CFR (coronary flow reserve) and HMR (hyperaemic microvascular resistance).</p>
</sec>
<sec><title>Results</title>
<p>From the analysed vessels, 18/18 vessels (100&#x0025;) presented a pathological CFR (&#x003C;2.5), indicative of coronary microvascular dysfunction (CMD), and 3/18 (17&#x0025;) demonstrated obstructive epicardial coronary disease (FFR&#x2009;&#x2264;&#x2009;0.8). A large proportion of vessels (15/18; 83&#x0025;) showed discordant FFR/CFR with preserved FFR and low CFR. 47&#x0025; of the coronary arteries in patients with AF and non-obstructive epicardial coronary disease presented structural CMD (HMR&#x2009;&#x2265;&#x2009;2.5&#x2005;mmHg/cm/s), and were associated with high BMR and an impaired response to adenosine. Conversely, vessels from patients with AF and non-obstructive epicardial coronary disease with functional CMD (HMR&#x2009;&#x003C;&#x2009;2.5&#x2005;mmHg/cm/s) showed higher bAPV. The permanent AF subpopulation presented increased values of HMR and BMR compared to persistent AF, while structural CMD was more often associated with persistent symptoms at 3 months, taking into account the limited sample size of our study.</p>
</sec>
<sec><title>Conclusion</title>
<p>Our findings highlight a systematically impaired CFR in patients with AF even in the absence of obstructive epicardial coronary disease, indicative of CMD. In addition, patients with AF presented more prevalent structural CMD (HMR&#x2009;&#x2265;&#x2009;2.5&#x2005;mmHg/cm/s), characterized by reduced hyperaemic responses to adenosine, possibly interfering with the FFR assessment.</p>
</sec>
</abstract>
<kwd-group>
<kwd>atrial fibrillation</kwd>
<kwd>CFR</kwd>
<kwd>FFR</kwd>
<kwd>HMR</kwd>
<kwd>microvascular dysfunction</kwd>
</kwd-group>
<contract-sponsor id="cn001">This study was supported by a grant from The Fund for Cardiac Surgery, Belgium.</contract-sponsor>
<counts>
<fig-count count="5"/>
<table-count count="4"/><equation-count count="0"/><ref-count count="45"/><page-count count="0"/><word-count count="0"/></counts><custom-meta-wrap><custom-meta><meta-name>section-at-acceptance</meta-name><meta-value>Cardiac Rhythmology</meta-value></custom-meta></custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="background"><title>Background</title>
<p>Atrial fibrillation (AF) is the most common arrhythmia and is associated with significant morbidity driven by heart failure and stroke, and an approximately two-fold increase in premature mortality (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B2">2</xref>). Around 5&#x0025;&#x2013;15&#x0025; of patients with AF will require coronary stenting (<xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B4">4</xref>). However, symptoms suggestive of myocardial ischemia are frequently encountered in patients with AF even in the absence of significant coronary artery disease, that seem to be attributed to myocardial oxygen supply-demand imbalance (<xref ref-type="bibr" rid="B5">5</xref>). These could be explained by abnormalities in coronary blood flow associated with AF, which are at the origin of impaired myocardial perfusion. Previous non-invasive studies suggest that patients with AF demonstrate diminished myocardial blood flow reserve and increased coronary vascular resistance indices (<xref ref-type="bibr" rid="B6">6</xref>&#x2013;<xref ref-type="bibr" rid="B9">9</xref>). Regarding the invasive assessment of coronary blood flow in patients with AF, data are sparse. A first physiological study using invasive coronary blood flow assessment in subjects with experimentally-induced AF found diminished coronary flow reserve (<xref ref-type="bibr" rid="B10">10</xref>). A more recent study showed that patients with AF without significant coronary artery disease had on average lower CFR values, inferring an association of AF with microvascular dysfunction, albeit in the absence of microcirculatory resistance indices measurements (<xref ref-type="bibr" rid="B11">11</xref>). Nonetheless, despite these two prior studies, an in-depth characterisation of coronary physiology in patients with AF is currently lacking. As such, we aim to provide an insight into the characteristics of coronary physiology in AF, by performing simultaneous invasive measurements of coronary flow- and pressure- indices in a real-life population of patients with AF and indication of coronary angiography.</p>
</sec>
<sec id="s2" sec-type="methods"><title>Methods</title>
<sec id="s2a"><title>Study population</title>
<p>This is a prospective open label study including patients with permanent or persistent AF and indication of coronary angiography (suspected chronic coronary syndrome based on clinical evaluation and non-invasive coronary imaging, or suspected acute coronary syndrome) showing intermediate coronary stenosis (40&#x0025;&#x2013;70&#x0025; visually-assessed stenosis diameter) requiring routine physiological assessment (<italic>n</italic>&#x2009;&#x003D;&#x2009;18 vessels from 14 patients). The AF was established to be permanent or persistent in accordance with the 2020 ESC guidelines on AF (<xref ref-type="bibr" rid="B12">12</xref>). Patients presented either permanent AF (<italic>n</italic>&#x2009;&#x003D;&#x2009;8 patients)&#x2014;a therapeutic attitude consisting of no additional attempts to restore sinus rhythm, or persistent AF (<italic>n</italic>&#x2009;&#x003D;&#x2009;6 patients)&#x2014;patients who were cardioverted (drugs or electrical cardioversion) usually by the end of the same hospitalization. The exclusion criteria were: cardiac arrest, cardiogenic shock, acute decompensated heart failure, acute phase of ST segment elevation myocardial infarction, culprit vessel in ST segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction, contraindications to adenosine administration (acute asthma, high degree atrioventricular block), and patients in sinus rhythm during the procedure. The prospective study was approved by the Ethical Committee of CHU Brugmann (reference number CE 2020/17). Informed consent was obtained from all patients undergoing investigation.</p>
</sec>
<sec id="s2b"><title>Cardiac catheterisation</title>
<p>We measured FFR (fractional flow reserve), and Doppler-derived coronary flow indices&#x2014;CFR (coronary flow reserve), BSR (basal stenosis resistance), HSR (hyperaemic stenosis resistance), BMR (basal microvascular resistance), and HMR (hyperaemic microvascular resistance) using a ComboWire&#x00AE; (Philips, Volcano) guidewire. Hemodynamic measurements were performed under basal conditions and under hyperaemia induced by intracoronary administration of adenosine (dose of 150&#x2005;&#x03BC;g, increased progressively until attaining maximal hyperaemia). CFR is calculated as the ratio of maximum blood flow during hyperaemia (hAPV&#x2014;hyperaemic average peak velocities) and resting coronary blood flow (bAPV&#x2014;baseline average peak velocities), and reflects both the epicardial and the microcirculatory coronary status (<xref ref-type="bibr" rid="B13">13</xref>). Given the irregular RR interval in AF with potential impact on coronary flow, APV was calculated as the average instantaneous peak velocity over an interval of 5 beats. HSR is a combined pressure- and flow-based index defined as the ratio of hyperaemic stenosis pressure gradient (Pa-Pd) and hAPV. A previous study has shown superior diagnostic accuracy of HSR compared to FFR or CFR for assessing the functional significance of epicardial coronary lesions in the general population (<xref ref-type="bibr" rid="B13">13</xref>), although is not currently implemented in day-to-day practice. Analogous to HSR, BSR is a combined pressure- and flow-based index that evaluates the epicardial coronary stenosis under basal conditions, being defined as the ratio of resting pressure gradient (Pa-Pd) and bAPV. The microvascular coronary resistances are reflected by BMR under resting conditions (resting Pd/bAPV), and by HMR after adenosine administration (hyperaemic Pd/hAPV) (<xref ref-type="bibr" rid="B14">14</xref>).</p>
</sec>
<sec id="s2c"><title>Distribution of coronary pressure- and flow-based indices in patients with AF</title>
<p>We assessed the agreement of CFR and FFR by evaluating the concordance of lesion classification obtained using the two techniques. Criteria for revascularization were FFR&#x2009;&#x2264;&#x2009;0.8 at maximal hyperaemia (<xref ref-type="bibr" rid="B15">15</xref>), and a CFR&#x2009;&#x003C;&#x2009;2.5 was considered indicative of coronary microvascular dysfunction (CMD) (<xref ref-type="bibr" rid="B16">16</xref>, <xref ref-type="bibr" rid="B17">17</xref>). In addition, we compared FFR to HSR values. HSR higher than 0.8&#x2005;mmHg/cm/s is associated with significant epicardial coronary artery disease (<xref ref-type="bibr" rid="B18">18</xref>).</p>
</sec>
<sec id="s2d"><title>Coronary physiological characteristics of patients with AF and non-obstructive epicardial disease</title>
<p>Patients with AF and non-obstructive epicardial coronary disease (FFR&#x2009;&#x003E;&#x2009;0.8; 15 vessels from 13 patients) were divided in two subgroups based on the presence of increased microvascular resistance [HMR&#x2009;&#x2265;&#x2009;2.5&#x2005;mmHg/cm/s (<xref ref-type="bibr" rid="B19">19</xref>, <xref ref-type="bibr" rid="B20">20</xref>)]. We compared patient and vessel characteristics between the two subgroups (HMR&#x2009;&#x003C;&#x2009;2.5&#x2005;mmHg/cm/s vs. HMR&#x2009;&#x2265;&#x2009;2.5&#x2005;mmHg/cm/s), including differences in pressure- and flow-based indices.</p>
</sec>
<sec id="s2e"><title>Clinical findings</title>
<p>In patients with non-obstructive epicardial coronary disease, the coronary physiology indices were compared based on the presence of permanent or persistent AF. In addition, the presence of persistent symptoms was evaluated at 3 months follow-up by the treating cardiologist. The symptoms motivating the coronary angiography were either chest pain or dyspnoea. A systematic differential diagnostic work-up performed prior to the coronary angiography (extensive blood work-up, chest imaging, echocardiography) excluded other potential causes for the presence of the above specified symptoms. Persistent symptoms were defined as the continuous presence of chest pain or dyspnoea at 3 months follow-up. The treating cardiologist was aware of the FFR values, but not of the values of flow-derived coronary indices, at the moment of clinical assessment.</p>
</sec>
<sec id="s2f"><title>Statistical analysis</title>
<p>Statistical analyses were performed using GraphPad Prism 9.0.1. Data are presented as mean&#x2009;&#x00B1;&#x2009;standard deviation. For analysing two groups we employed the Mann-Whitney <italic>U</italic> test. Categorical variables were compared using Chi-square test. Correlation analyses were performed using Spearman&#x0027;s correlation test. The maximum hyperaemic response was analysed using two-way ANOVA, followed by Tukey post-hoc test. Significance level was set at 0.05.</p>
</sec>
</sec>
<sec id="s3" sec-type="results"><title>Results</title>
<sec id="s3a"><title>Study population</title>
<p>We performed combined assessment of coronary pressure- and flow-derived indices of a total of 18 vessels from 14 patients with AF. The demographic and clinical characteristics of these patients are summarised in <xref ref-type="table" rid="T1">Table&#x00A0;1</xref>, and of the corresponding vessels in <xref ref-type="table" rid="T2">Table&#x00A0;2</xref>.</p>
<table-wrap id="T1" position="float"><label>Table 1</label>
<caption><p>Characteristics of the study population (<italic>n&#x2009;</italic>&#x003D;&#x2009;14 patients).</p></caption>
<table frame="hsides" rules="groups">
<colgroup>
<col align="left"/>
<col align="center"/>
</colgroup>
<tbody>
<tr>
<td valign="top" align="left">Age (years)</td>
<td valign="top" align="center">76.0&#x2009;&#x00B1;&#x2009;9.4</td>
</tr>
<tr>
<td valign="top" align="left">Women/Men (&#x0025; Women)</td>
<td valign="top" align="center">5/9 (35.7&#x0025;)</td>
</tr>
<tr>
<td valign="top" align="left">BMI (kg/m<sup>2</sup>)</td>
<td valign="top" align="center">25.6&#x2009;&#x00B1;&#x2009;4.8</td>
</tr>
<tr>
<td valign="top" align="left" colspan="2">Cardiovascular risk factors</td>
</tr>
<tr>
<td valign="top" align="left">&#x2013;&#x2002;Diabetes Y/N (&#x0025;Y)</td>
<td valign="top" align="center">7/7 (50.0&#x0025;)</td>
</tr>
<tr>
<td valign="top" align="left">&#x2013;&#x2002;Hypertension Y/N (&#x0025;Y)</td>
<td valign="top" align="center">11/3 (78.6&#x0025;)</td>
</tr>
<tr>
<td valign="top" align="left">&#x2013;&#x2002;Hypercholesterolemia Y/N (&#x0025;Y)</td>
<td valign="top" align="center">10/4 (71.4&#x0025;)</td>
</tr>
<tr>
<td valign="top" align="left">&#x2013;&#x2002;Former smoker Y/N (&#x0025;Y)</td>
<td valign="top" align="center">6/8 (42.9&#x0025;)</td>
</tr>
<tr>
<td valign="top" align="left">&#x2013;&#x2002;Current smoker Y/N (&#x0025;Y)</td>
<td valign="top" align="center">2/12 (14.3&#x0025;)</td>
</tr>
<tr>
<td valign="top" align="left">&#x2013;&#x2002;Prior ACS Y/N (&#x0025;Y)</td>
<td valign="top" align="center">2/12 (14.3&#x0025;)</td>
</tr>
<tr>
<td valign="top" align="left">&#x2013;&#x2002;Prior PCI Y/N (&#x0025;Y)</td>
<td valign="top" align="center">2/12 (14.3&#x0025;)</td>
</tr>
<tr>
<td valign="top" align="left">Heart rate (bpm)</td>
<td valign="top" align="center">81.9&#x2009;&#x00B1;&#x2009;15.7</td>
</tr>
<tr>
<td valign="top" align="left">BP systolic (mmHg)</td>
<td valign="top" align="center">124.9&#x2009;&#x00B1;&#x2009;23.5</td>
</tr>
<tr>
<td valign="top" align="left">BP diastolic (mmHg)</td>
<td valign="top" align="center">72.9&#x2009;&#x00B1;&#x2009;12.1</td>
</tr>
<tr>
<td valign="top" align="left">ACS indication Y/N (&#x0025;Y)</td>
<td valign="top" align="center">4/10 (28.6&#x0025;)</td>
</tr>
<tr>
<td valign="top" align="left">LVEF (&#x0025;)</td>
<td valign="top" align="center">55.4&#x2009;&#x00B1;&#x2009;10.1</td>
</tr>
<tr>
<td valign="top" align="left">HFpEF Y/N (&#x0025;Y)</td>
<td valign="top" align="center">12/2 (85.7&#x0025;)</td>
</tr>
<tr>
<td valign="top" align="left">HFrEF Y/N (&#x0025;Y)</td>
<td valign="top" align="center">2/12 (14.3&#x0025;)</td>
</tr>
<tr>
<td valign="top" align="left">Cardiac index (L/min/m<sup>2</sup>)</td>
<td valign="top" align="center">3.4&#x2009;&#x00B1;&#x2009;0.9</td>
</tr>
<tr>
<td valign="top" align="left">Peak NT-proBNP (ng/L)</td>
<td valign="top" align="center">2880.8&#x2009;&#x00B1;&#x2009;1788.7</td>
</tr>
<tr>
<td valign="top" align="left">Peak Troponin (ng/L)</td>
<td valign="top" align="center">110.1&#x2009;&#x00B1;&#x2009;135.4</td>
</tr>
<tr>
<td valign="top" align="left">Beta-blockers Y/N</td>
<td valign="top" align="center">11/3 (78.6&#x0025;)</td>
</tr>
<tr>
<td valign="top" align="left">RAAS inhibitors Y/N</td>
<td valign="top" align="center">9/5 (64.3&#x0025;)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1"><p>Values are presented as mean&#x2009;&#x00B1;&#x2009;standard deviation, or group proportions. ACS, acute coronary syndrome; BMI, body mass index; BP, blood pressure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; LVEF, left ventricular ejection fraction; PCI, percutaneous coronary intervention; RAAS, renin-angiotensin-aldosterone system. Cardiac index assessed by transthoracic echocardiography.</p></fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="T2" position="float"><label>Table 2</label>
<caption><p>Physiological assessment of coronary circulation (<italic>n</italic>&#x2009;&#x003D;&#x2009;18 vessels).</p></caption>
<table frame="hsides" rules="groups">
<colgroup>
<col align="left"/>
<col align="center"/>
<col align="center"/>
</colgroup>
<thead>
<tr>
<th valign="top" align="left" rowspan="2"/>
<th valign="top" align="center">FFR&#x2009;&#x003E;&#x2009;0.8</th>
<th valign="top" align="center">FFR&#x2009;&#x2264;&#x2009;0.8</th>
</tr>
<tr>
<th valign="top" align="center"><italic>n</italic>&#x2009;&#x003D;&#x2009;15</th>
<th valign="top" align="center"><italic>n</italic>&#x2009;&#x003D;&#x2009;3</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left" colspan="3">Artery studied</td>
</tr>
<tr>
<td valign="top" align="left">&#x2013;&#x2002;LAD/LCX/RCA/Other</td>
<td valign="top" align="center">8/2/2/3</td>
<td valign="top" align="center">3/0/0/0</td>
</tr>
<tr>
<td valign="top" align="left" colspan="3">Hemodynamic assessment of epicardial disease</td>
</tr>
<tr>
<td valign="top" align="left">&#x2013;&#x2002;FFR</td>
<td valign="top" align="center">0.89&#x2009;&#x00B1;&#x2009;0.05</td>
<td valign="top" align="center">0.67&#x2009;&#x00B1;&#x2009;0.07</td>
</tr>
<tr>
<td valign="top" align="left">&#x2013;&#x2002;HSR (mmHg/cm/s)</td>
<td valign="top" align="center">0.25&#x2009;&#x00B1;&#x2009;0.20</td>
<td valign="top" align="center">0.68&#x2009;&#x00B1;&#x2009;0.56</td>
</tr>
<tr>
<td valign="top" align="left">&#x2013;&#x2002;BSR</td>
<td valign="top" align="center">0.20&#x2009;&#x00B1;&#x2009;0.20</td>
<td valign="top" align="center">0.56&#x2009;&#x00B1;&#x2009;0.38</td>
</tr>
<tr>
<td valign="top" align="left">&#x2013;&#x2002;bAPV (cm/s)</td>
<td valign="top" align="center">27.5&#x2009;&#x00B1;&#x2009;19.5</td>
<td valign="top" align="center">46.3&#x2009;&#x00B1;&#x2009;23.7</td>
</tr>
<tr>
<td valign="top" align="left">&#x2013;&#x2002;hAPV (cm/s)</td>
<td valign="top" align="center">47.2&#x2009;&#x00B1;&#x2009;30.6</td>
<td valign="top" align="center">66.0&#x2009;&#x00B1;&#x2009;38.1</td>
</tr>
<tr>
<td valign="top" align="left">&#x2013;&#x2002;Pa</td>
<td valign="top" align="center">93.1&#x2009;&#x00B1;&#x2009;14.5</td>
<td valign="top" align="center">93.3&#x2009;&#x00B1;&#x2009;37.6</td>
</tr>
<tr>
<td valign="top" align="left">&#x2013;&#x2002;Pd</td>
<td valign="top" align="center">88.5&#x2009;&#x00B1;&#x2009;14.4</td>
<td valign="top" align="center">73.3&#x2009;&#x00B1;&#x2009;29.5</td>
</tr>
<tr>
<td valign="top" align="left">&#x2013;&#x2002;QCA-DS&#x0025;</td>
<td valign="top" align="center">53.2&#x2009;&#x00B1;&#x2009;7.6</td>
<td valign="top" align="center">83.7&#x2009;&#x00B1;&#x2009;8.0</td>
</tr>
<tr>
<td valign="top" align="left">&#x2013;&#x2002;QCA-length (mm)</td>
<td valign="top" align="center">14.5&#x2009;&#x00B1;&#x2009;7.1</td>
<td valign="top" align="center">44.7&#x2009;&#x00B1;&#x2009;7.0</td>
</tr>
<tr>
<td valign="top" align="left" colspan="3">Assessment of the microvasculature</td>
</tr>
<tr>
<td valign="top" align="left">&#x2013;&#x2002;CFR</td>
<td valign="top" align="center">1.74&#x2009;&#x00B1;&#x2009;0.24</td>
<td valign="top" align="center">1.40&#x2009;&#x00B1;&#x2009;0.17</td>
</tr>
<tr>
<td valign="top" align="left">&#x2013;&#x2002;HMR (mmHg/cm/s)</td>
<td valign="top" align="center">2.57&#x2009;&#x00B1;&#x2009;1.34</td>
<td valign="top" align="center">1.63&#x2009;&#x00B1;&#x2009;1.19</td>
</tr>
<tr>
<td valign="top" align="left">&#x2013;&#x2002;Increased microvascular resistance (HMR&#x2009;&#x2265;&#x2009;2.5&#x2005;mmHg/cm/s) Y/N (&#x0025;Y)</td>
<td valign="top" align="center">7/8 (46.6&#x0025;)</td>
<td valign="top" align="center">1/2 (33.3&#x0025;)</td>
</tr>
<tr>
<td valign="top" align="left">&#x2013;&#x2002;BMR (mmHg/cm/s)</td>
<td valign="top" align="center">3.47&#x2009;&#x00B1;&#x2009;1.39</td>
<td valign="top" align="center">2.73&#x2009;&#x00B1;&#x2009;1.29</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2"><p>Values are presented as mean&#x2009;&#x00B1;&#x2009;standard deviation, or group proportions. APV average peak velocity; BMR, basal microvascular resistance; BP, blood pressure; BSR, basal stenosis resistance; CFR, coronary flow reserve; DS, diameter stenosis; FFR, fractional flow reserve; HMR, hyperaemic microvascular resistance; HSR, hyperaemic stenosis resistance; LAD, left anterior descending artery; QCA, quantitative coronary angiography.</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="s3b"><title>Distribution of coronary pressure- and flow-based indices in patients with AF</title>
<p>From the analysed vessels, 18/18 vessels (100&#x0025;) presented a pathological CFR (&#x003C;2.5), and only 3/18 (17&#x0025;) demonstrated obstructive epicardial coronary disease (FFR&#x2009;&#x2264;&#x2009;0.8) requiring percutaneous coronary angioplasty. These 3 pathological vessels were distributed in 3 different patients, 2 of which showed one vessel with pathological FFR, and one vessel with non-pathological FFR. As such, most vessels (15/18; 83&#x0025;) showed discordant FFR/CFR with preserved FFR and low CFR, while 3/18 (17&#x0025;) showed concordant FFR/CFR with low FFR and low CFR (<xref ref-type="fig" rid="F1">Figure&#x00A0;1A</xref>). We detected a moderate correlation between FFR and CFR (r&#x2009;&#x003D;&#x2009;0.5840, <italic>p</italic>&#x2009;&#x003D;&#x2009;0.0109; Spearman correlation) (<xref ref-type="fig" rid="F1">Figure&#x00A0;1B</xref>).</p>
<fig id="F1" position="float"><label>Figure 1</label>
<caption><p><sc>(</sc><bold>A</bold><sc>)</sc> Agreement between FFR and CFR indices in patients with AF. (<bold>B</bold>) Correlation analysis between FFR and CFR in patients with AF. Spearman correlation. AF, atrial fibrillation; CFR, coronary flow reserve; FFR, fractional flow reserve.</p></caption>
<graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="fcvm-10-1206743-g001.tif"/>
</fig>
</sec>
<sec id="s3c"><title>Coronary physiological characteristics of patients with AF and non-obstructive epicardial disease</title>
<p>Vessels of patients with AF and non-obstructive epicardial disease (FFR&#x2009;&#x003E;&#x2009;0.8) presented low CFR values (mean value of 1.74&#x2009;&#x00B1;&#x2009;0.24), indicative of CMD. There was no correlation between the CFR values and the left ventricular ejection fraction, or the cardiac index assessed by transthoracic echocardiography (<italic>p</italic>&#x2009;&#x003E;&#x2009;0.05; Spearman correlation) as to explain the observed low CFR values. Using the described cut-off of 2.5&#x2005;mmHg/cm/s for pathological HMR (<xref ref-type="bibr" rid="B19">19</xref>, <xref ref-type="bibr" rid="B20">20</xref>), and the pattern of structural/functional CMD identified in the general population (<xref ref-type="bibr" rid="B16">16</xref>), we divided the vessels of patients with AF and non-obstructive epicardial disease as presenting structural CMD (HMR&#x2009;&#x2265;&#x2009;2.5&#x2005;mmHg/cm/s; 7 coronary arteries and 6 patients) or functional CMD (HMR&#x2009;&#x003C;&#x2009;2.5&#x2005;mmHg/cm/s; 8 coronary arteries and 7 patients) (<xref ref-type="table" rid="T3">Tables&#x00A0;3</xref>, <xref ref-type="table" rid="T4">4</xref>). The subgroup of vessels with structural CMD demonstrated significantly higher BMR values compared to the vessels with functional CMD (4.34&#x2009;&#x00B1;&#x2009;0.67&#x2005;mmHg/cm/s vs. 2.71&#x2009;&#x00B1;&#x2009;1.43&#x2005;mmHg/cm/s; <italic>p</italic>&#x2009;&#x003D;&#x2009;0.0289) (<xref ref-type="table" rid="T4">Table&#x00A0;4</xref>). High HMR was associated with a reduced microvascular response to adenosine defined as 100-(HMR/BMR) (&#x0025;) when compared to low HMR (13.6&#x2009;&#x00B1;&#x2009;11.4&#x0025; vs. 37.5&#x2009;&#x00B1;&#x2009;16.7&#x0025;; <italic>p</italic>&#x2009;&#x003D;&#x2009;0.0093) (<xref ref-type="fig" rid="F2">Figure&#x00A0;2A</xref>). In addition, there was a moderate inverse correlation between HMR values and the microvascular response to adenosine (<xref ref-type="fig" rid="F2">Figure&#x00A0;2B</xref>) (r&#x2009;&#x003D;&#x2009;&#x2212;0.6429, <italic>p</italic>&#x2009;&#x003D;&#x2009;0.0116; Spearman correlation). In line with these findings, the maximum hyperaemic effect in vessels of patients with non-obstructive epicardial disease was found to depend on the presence of increased microvascular resistance, as adenosine administration led to a significant decrease in Pd/Pa only in vessels with HMR&#x2009;&#x003C;&#x2009;2.5 mmHg/cm/s (<xref ref-type="fig" rid="F2">Figure&#x00A0;2C</xref>). A more detailed look at the clinical and lesion characteristics of patients with non-obstructive epicardial disease according to the presence of increased microvascular resistance is overviewed in <xref ref-type="table" rid="T3">Tables&#x00A0;3</xref>, <xref ref-type="table" rid="T4">4</xref>. The subgroup with functional CMD presented higher bAPV (36.4&#x2009;&#x00B1;&#x2009;23.4&#x2005;cm/s vs. 17.4&#x2009;&#x00B1;&#x2009;4.9&#x2005;cm/s; <italic>p</italic>&#x2009;&#x003D;&#x2009;0.0294) and hAPV (62.4&#x2009;&#x00B1;&#x2009;34.8&#x2005;cm/s vs. 29.8&#x2009;&#x00B1;&#x2009;10.7&#x2005;cm/s; <italic>p</italic>&#x2009;&#x003D;&#x2009;0.0347) compared to the subgroup with structural CMD.</p>
<table-wrap id="T3" position="float"><label>Table 3</label>
<caption><p>Characteristics of patients with AF and non-obstructive epicardial coronary disease, presenting structural (HMR&#x2009;&#x2265;&#x2009;2.5&#x2005;mmHg/cm/s) or functional (HMR&#x2009;&#x003C;&#x2009;2.5&#x2005;mmHg/cm/s) CMD (<italic>n</italic>&#x2009;&#x003D;&#x2009;13 patients).</p></caption>
<table frame="hsides" rules="groups">
<colgroup>
<col align="left"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup>
<thead>
<tr>
<th valign="top" align="left" rowspan="2"/>
<th valign="top" align="center">Functional CMD (HMR&#x2009;&#x003C;&#x2009;2.5 mmHg/cm/s)</th>
<th valign="top" align="center">Structural CMD (HMR&#x2009;&#x2265;&#x2009;2.5 mmHg/cm/s)</th>
<th valign="top" align="center" rowspan="2"><italic>P</italic></th>
</tr>
<tr>
<th valign="top" align="center"><italic>n</italic>&#x2009;&#x003D;&#x2009;7</th>
<th valign="top" align="center"><italic>n</italic>&#x2009;&#x003D;&#x2009;6</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">Age (years)</td>
<td valign="top" align="center">74.6&#x2009;&#x00B1;&#x2009;11.7</td>
<td valign="top" align="center">78.9&#x2009;&#x00B1;&#x2009;6.5</td>
<td valign="top" align="center">0.836</td>
</tr>
<tr>
<td valign="top" align="left">Women/Men</td>
<td valign="top" align="center">2/5</td>
<td valign="top" align="center">3/3</td>
<td valign="top" align="center">0.428</td>
</tr>
<tr>
<td valign="top" align="left">Diabetes Y/N</td>
<td valign="top" align="center">3/4</td>
<td valign="top" align="center">3/3</td>
<td valign="top" align="center">0.796</td>
</tr>
<tr>
<td valign="top" align="left">Hypertension Y/N</td>
<td valign="top" align="center">5/2</td>
<td valign="top" align="center">5/1</td>
<td valign="top" align="center">0.611</td>
</tr>
<tr>
<td valign="top" align="left">Hypercholesterolemia Y/N</td>
<td valign="top" align="center">5/2</td>
<td valign="top" align="center">4/2</td>
<td valign="top" align="center">0.852</td>
</tr>
<tr>
<td valign="top" align="left">Kidney failure Y/N</td>
<td valign="top" align="center">2/5</td>
<td valign="top" align="center">2/4</td>
<td valign="top" align="center">0.852</td>
</tr>
<tr>
<td valign="top" align="left">LVEF (&#x0025;)</td>
<td valign="top" align="center">54.0&#x2009;&#x00B1;&#x2009;9.4</td>
<td valign="top" align="center">57.0&#x2009;&#x00B1;&#x2009;12.2</td>
<td valign="top" align="center">0.509</td>
</tr>
<tr>
<td valign="top" align="left">HFpEF Y/N</td>
<td valign="top" align="center">6/1</td>
<td valign="top" align="center">5/1</td>
<td valign="top" align="center">0.905</td>
</tr>
<tr>
<td valign="top" align="left">HFrEF Y/N</td>
<td valign="top" align="center">1/6</td>
<td valign="top" align="center">1/5</td>
<td valign="top" align="center">0.905</td>
</tr>
<tr>
<td valign="top" align="left">Cardiac index (L/min/m<sup>2</sup>)</td>
<td valign="top" align="center">3.08&#x2009;&#x00B1;&#x2009;0.78</td>
<td valign="top" align="center">3.54&#x2009;&#x00B1;&#x2009;0.91</td>
<td valign="top" align="center">0.484</td>
</tr>
<tr>
<td valign="top" align="left">LV filling pressure Normal/High</td>
<td valign="top" align="center">3/4</td>
<td valign="top" align="center">3/2</td>
<td valign="top" align="center">0.558</td>
</tr>
<tr>
<td valign="top" align="left">Peak NT-proBNP (ng/L)</td>
<td valign="top" align="center">2865.2&#x2009;&#x00B1;&#x2009;1743.8</td>
<td valign="top" align="center">3533.3&#x2009;&#x00B1;&#x2009;2075.9</td>
<td valign="top" align="center">0.786</td>
</tr>
<tr>
<td valign="top" align="left">Peak Troponin (ng/L)</td>
<td valign="top" align="center">161.4&#x2009;&#x00B1;&#x2009;168.1</td>
<td valign="top" align="center">54.6&#x2009;&#x00B1;&#x2009;46.9</td>
<td valign="top" align="center">0.171</td>
</tr>
<tr>
<td valign="top" align="left">Chest pain Y/N</td>
<td valign="top" align="center">4/3</td>
<td valign="top" align="center">2/4</td>
<td valign="top" align="center">0.390</td>
</tr>
<tr>
<td valign="top" align="left">Dyspnoea Y/N</td>
<td valign="top" align="center">3/4</td>
<td valign="top" align="center">4/2</td>
<td valign="top" align="center">0.390</td>
</tr>
<tr>
<td valign="top" align="left">ACS indication Y/N</td>
<td valign="top" align="center">3/4</td>
<td valign="top" align="center">1/5</td>
<td valign="top" align="center">0.307</td>
</tr>
<tr>
<td valign="top" align="left">Positive NCI Y/N</td>
<td valign="top" align="center">5/2</td>
<td valign="top" align="center">4/2</td>
<td valign="top" align="center">0.852</td>
</tr>
<tr>
<td valign="top" align="left">3-mo persistent symptoms Y/N</td>
<td valign="top" align="center">0/7</td>
<td valign="top" align="center">5/1</td>
<td valign="top" align="center">&#x003C;0.01</td>
</tr>
<tr>
<td valign="top" align="left">Permanent/Persistent AF</td>
<td valign="top" align="center">2/5</td>
<td valign="top" align="center">6/0</td>
<td valign="top" align="center">&#x003C;0.01</td>
</tr>
<tr>
<td valign="top" align="left">Beta-blockers Y/N</td>
<td valign="top" align="center">6/1</td>
<td valign="top" align="center">4/2</td>
<td valign="top" align="center">0.416</td>
</tr>
<tr>
<td valign="top" align="left">RAAS inhibitors Y/N</td>
<td valign="top" align="center">5/2</td>
<td valign="top" align="center">3/3</td>
<td valign="top" align="center">0.428</td>
</tr>
<tr>
<td valign="top" align="left">Heart rate (bpm)</td>
<td valign="top" align="center">76.7&#x2009;&#x00B1;&#x2009;14.8</td>
<td valign="top" align="center">81.7&#x2009;&#x00B1;&#x2009;6.7</td>
<td valign="top" align="center">0.558</td>
</tr>
<tr>
<td valign="top" align="left">Heart rate Beat-to-beat variability (CV&#x0025;)</td>
<td valign="top" align="center">0.12&#x2009;&#x00B1;&#x2009;0.05</td>
<td valign="top" align="center">0.12&#x2009;&#x00B1;&#x2009;0.04</td>
<td valign="top" align="center">0.947</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3"><p>Values are presented as mean&#x2009;&#x00B1;&#x2009;standard deviation, or group proportions. <italic>P</italic> values were determined using Mann-Whitney <italic>U</italic> test, or Chi-square test respectively. ACS, acute coronary syndrome; AF, atrial fibrillation; CMD, coronary microvascular dysfunction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; LVEF, left ventricular ejection fraction; NCI, non-invasive coronary imaging; QCA, quantitative coronary angiography; RAAS, renin-angiotensin-aldosterone system. Cardiac index assessed by transthoracic echocardiography.</p></fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="T4" position="float"><label>Table 4</label>
<caption><p>Characteristics of vessels with AF and non-obstructive epicardial coronary disease, presenting structural (HMR&#x2009;&#x2265;&#x2009;2.5&#x2005;mmHg/cm/s) or functional (HMR&#x2009;&#x003C;&#x2009;2.5&#x2005;mmHg/cm/s) CMD (<italic>n</italic>&#x2009;&#x003D;&#x2009;15 vessels).</p></caption>
<table frame="hsides" rules="groups">
<colgroup>
<col align="left"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup>
<thead>
<tr>
<th valign="top" align="left" rowspan="2"/>
<th valign="top" align="center">Functional CMD (HMR&#x2009;&#x003C;&#x2009;2.5&#x2005;mmHg/cm/s)</th>
<th valign="top" align="center">Structural CMD (HMR&#x2009;&#x2265;&#x2009;2.5&#x2005;mmHg/cm/s)</th>
<th valign="top" align="center" rowspan="2"><italic>P</italic></th>
</tr>
<tr>
<th valign="top" align="center"><italic>n</italic>&#x2009;&#x003D;&#x2009;8</th>
<th valign="top" align="center"><italic>n</italic>&#x2009;&#x003D;&#x2009;7</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">LAD/LCX/RCA/Other</td>
<td valign="top" align="center">4/1/1/2</td>
<td valign="top" align="center">4/1/1/1</td>
<td valign="top" align="center">0.966</td>
</tr>
<tr>
<td valign="top" align="left">QCA-DS&#x0025;</td>
<td valign="top" align="center">51.6&#x2009;&#x00B1;&#x2009;8.3</td>
<td valign="top" align="center">55.0&#x2009;&#x00B1;&#x2009;.8</td>
<td valign="top" align="center">0.749</td>
</tr>
<tr>
<td valign="top" align="left">QCA-length (mm)</td>
<td valign="top" align="center">14.7&#x2009;&#x00B1;&#x2009;6.9</td>
<td valign="top" align="center">14.3&#x2009;&#x00B1;&#x2009;7.9</td>
<td valign="top" align="center">0.942</td>
</tr>
<tr>
<td valign="top" align="left">Resting Pd/Pa</td>
<td valign="top" align="center">0.96&#x2009;&#x00B1;&#x2009;0.03</td>
<td valign="top" align="center">0.94&#x2009;&#x00B1;&#x2009;0.04</td>
<td valign="top" align="center">0.927</td>
</tr>
<tr>
<td valign="top" align="left">FFR</td>
<td valign="top" align="center">0.89&#x2009;&#x00B1;&#x2009;0.06</td>
<td valign="top" align="center">0.89&#x2009;&#x00B1;&#x2009;0.04</td>
<td valign="top" align="center">0.976</td>
</tr>
<tr>
<td valign="top" align="left">CFR</td>
<td valign="top" align="center">1.80&#x2009;&#x00B1;&#x2009;0.26</td>
<td valign="top" align="center">1.67&#x2009;&#x00B1;&#x2009;0.23</td>
<td valign="top" align="center">0.391</td>
</tr>
<tr>
<td valign="top" align="left">HSR (mmHg/cm/s)</td>
<td valign="top" align="center">0.16&#x2009;&#x00B1;&#x2009;0.14</td>
<td valign="top" align="center">0.35&#x2009;&#x00B1;&#x2009;0.21</td>
<td valign="top" align="center">0.077</td>
</tr>
<tr>
<td valign="top" align="left">HMR (mmHg/cm/s)</td>
<td valign="top" align="center">1.54&#x2009;&#x00B1;&#x2009;0.64</td>
<td valign="top" align="center">3.76&#x2009;&#x00B1;&#x2009;0.78</td>
<td valign="top" align="center">&#x003C;0.001</td>
</tr>
<tr>
<td valign="top" align="left">BMR (mmHg/cm/s)</td>
<td valign="top" align="center">2.71&#x2009;&#x00B1;&#x2009;1.43</td>
<td valign="top" align="center">4.34&#x2009;&#x00B1;&#x2009;0.67</td>
<td valign="top" align="center">&#x003C;0.05</td>
</tr>
<tr>
<td valign="top" align="left">BSR</td>
<td valign="top" align="center">0.12&#x2009;&#x00B1;&#x2009;0.09</td>
<td valign="top" align="center">0.27&#x2009;&#x00B1;&#x2009;0.26</td>
<td valign="top" align="center">0.304</td>
</tr>
<tr>
<td valign="top" align="left">HMR/(HMR&#x2009;&#x002B;&#x2009;HSR)</td>
<td valign="top" align="center">0.91&#x2009;&#x00B1;&#x2009;0.06</td>
<td valign="top" align="center">0.92&#x2009;&#x00B1;&#x2009;0.04</td>
<td valign="top" align="center">&#x003E;0.99</td>
</tr>
<tr>
<td valign="top" align="left">Microcirculatory resistance response to adenosine 100&#x2014;(HMR/BMR) (&#x0025;)</td>
<td valign="top" align="center">37.5&#x2009;&#x00B1;&#x2009;16.7</td>
<td valign="top" align="center">13.6&#x2009;&#x00B1;&#x2009;11.4</td>
<td valign="top" align="center">&#x003C;0.01</td>
</tr>
<tr>
<td valign="top" align="left">bAPV (cm/s)</td>
<td valign="top" align="center">36.4&#x2009;&#x00B1;&#x2009;23.4</td>
<td valign="top" align="center">17.4&#x2009;&#x00B1;&#x2009;4.9</td>
<td valign="top" align="center">&#x003C;0.05</td>
</tr>
<tr>
<td valign="top" align="left">hAPV (cm/s)</td>
<td valign="top" align="center">62.4&#x2009;&#x00B1;&#x2009;34.8</td>
<td valign="top" align="center">29.8&#x2009;&#x00B1;&#x2009;10.7</td>
<td valign="top" align="center">&#x003C;0.05</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn4"><p>Values are presented as mean&#x2009;&#x00B1;&#x2009;standard deviation, or group proportions. <italic>P</italic> values were determined using Mann-Whitney <italic>U</italic> test, or Chi-square test respectively. bAPV baseline average peak velocity; BMR, basal microvascular resistance; BSR, basal stenosis resistance; CFR, coronary flow reserve; CMD, coronary microvascular dysfunction; DS, diameter stenosis; FFR, fractional flow reserve; hAPV, hyperaemic average peak velocity; HMR, hyperaemic microvascular resistance; HSR, hyperaemic stenosis resistance; LAD, left anterior descending artery; QCA, quantitative coronary angiography.</p></fn>
</table-wrap-foot>
</table-wrap>
<fig id="F2" position="float"><label>Figure 2</label>
<caption><p>(<bold>A</bold>) Microvascular response to adenosine defined as 100-(HMR/BMR) (&#x0025;) in patients with AF and non-obstructive epicardial coronary disease, presenting structural (HMR&#x2009;&#x2265;&#x2009;2.5&#x2005;mmHg/cm/s) or functional (HMR&#x2009;&#x003C;&#x2009;2.5&#x2005;mmHg/cm/s) CMD. Data are presented as mean&#x2009;&#x00B1;&#x2009;standard deviation, and analysed using a Mann-Whitney <italic>U</italic> test, &#x002A;&#x002A;<italic>p&#x2009;</italic>&#x003C;&#x2009;0.01. (<bold>B</bold>) Correlation between HMR and the microvascular response to adenosine in patients with AF and non-obstructive epicardial disease. Spearman correlation. (<bold>C</bold>) The maximum hyperaemic effect in patients with AF and non-obstructive epicardial disease, presenting structural (HMR&#x2009;&#x2265;&#x2009;2.5&#x2005;mmHg/cm/s) or functional (HMR&#x2009;&#x003C;&#x2009;2.5&#x2005;mmHg/cm/s) CMD. Data are presented as mean&#x2009;&#x00B1;&#x2009;standard deviation, and analysed using a two-way ANOVA test followed by Tukey&#x0027;s post-hoc test, &#x002A;<italic>p&#x2009;</italic>&#x003C;&#x2009;0.05. AF, atrial fibrillation; BMR, basal microvascular resistance; CFR, coronary flow reserve; CMD, coronary microvascular dysfunction; FFR, fractional flow reserve; HMR, hyperaemic microvascular resistance.</p></caption>
<graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="fcvm-10-1206743-g002.tif"/>
</fig>
</sec>
<sec id="s3d"><title>Clinical findings</title>
<p>Patients with structural CMD demonstrated significantly more persistent symptoms (chest pain or dyspnoea) at 3 months following invasive assessment (83.3&#x0025; vs. 0.00&#x0025;, <italic>p</italic>&#x2009;&#x003D;&#x2009;0.0021) compared to functional CMD (<xref ref-type="fig" rid="F3">Figure&#x00A0;3</xref>). Furthermore, permanent AF was more often associated with high HMR (3.13&#x2009;&#x00B1;&#x2009;1.20&#x2005;mmHg/cm/s vs. 1.46&#x2009;&#x00B1;&#x2009;0.79&#x2005;mmHg/cm/s, <italic>p</italic>&#x2009;&#x003D;&#x2009;0.0193) (<xref ref-type="fig" rid="F4">Figure&#x00A0;4A</xref>) and high BMR (4.16&#x2009;&#x00B1;&#x2009;0.83&#x2005;mmHg/cm/s vs. 2.10&#x2009;&#x00B1;&#x2009;1.26&#x2005;mmHg/cm/s, <italic>p</italic>&#x2009;&#x003D;&#x2009;0.0127) (<xref ref-type="fig" rid="F4">Figure&#x00A0;4B</xref>) compared to persistent AF.</p>
<fig id="F3" position="float"><label>Figure 3</label>
<caption><p>Presence of persistent symptoms (chest pain or dyspnoea) at 3 months following invasive assessment in patients with AF and non-obstructive epicardial coronary disease, presenting structural (HMR&#x2009;&#x2265;&#x2009;2.5&#x2005;mmHg/cm/s) or functional (HMR&#x2009;&#x003C;&#x2009;2.5&#x2005;mmHg/cm/s) CMD. Chi-square test, &#x002A;&#x002A;<italic>p&#x2009;</italic>&#x003C;&#x2009;0.01. AF, atrial fibrillation; CMD, coronary microvascular dysfunction; HMR, hyperaemic microvascular resistance.</p></caption>
<graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="fcvm-10-1206743-g003.tif"/>
</fig>
<fig id="F4" position="float"><label>Figure 4</label>
<caption><p>HMR (<bold>A</bold>) and BMR (<bold>B</bold>) in patients with permanent or persistent AF, and non-obstructive epicardial disease. Data are presented as mean&#x2009;&#x00B1;&#x2009;standard deviation, and analysed using a Mann-Whitney <italic>U</italic> test, &#x002A;<italic>p&#x2009;</italic>&#x003C;&#x2009;0.05. AF, atrial fibrillation; BMR, basal microvascular resistance; HMR, hyperaemic microvascular resistance.</p></caption>
<graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="fcvm-10-1206743-g004.tif"/>
</fig>
<p>Regarding the functional evaluation of coronary stenosis severity, there was high agreement in the classification of the lesions between FFR and HSR (83&#x0025;), with the two indices showing strong correlation across all patients with AF (r&#x2009;&#x003D;&#x2009;&#x2212;0.7446, <italic>p</italic>&#x2009;&#x003D;&#x2009;0.0004; Spearman correlation) (<xref ref-type="fig" rid="F5">Figure&#x00A0;5A</xref>). Moreover, FFR values correlated strongly with the microvascular component of total vascular resistance, defined as HMR/(HMR&#x2009;&#x002B;&#x2009;HSR) (r&#x2009;&#x003D;&#x2009;0.9866, <italic>p</italic>&#x2009;&#x003C;&#x2009;0.0001; Spearman correlation) (<xref ref-type="fig" rid="F5">Figure&#x00A0;5B</xref>).</p>
<fig id="F5" position="float"><label>Figure 5</label>
<caption><p>(<bold>A</bold>) Agreement between FFR and HSR in evaluating coronary stenosis severity in patients with AF. (<bold>B</bold>) Correlation between FFR values and the microvascular component of total vascular resistance, defined as HMR/(HMR&#x2009;&#x002B;&#x2009;HSR) in patients with AF. Spearman correlation. AF, atrial fibrillation; FFR, fractional flow reserve; HMR, hyperaemic microvascular resistance; HSR, hyperaemic stenosis resistance.</p></caption>
<graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="fcvm-10-1206743-g005.tif"/>
</fig>
</sec>
</sec>
<sec id="s4" sec-type="discussion"><title>Discussion</title>
<p>In the present study, our main findings indicate that: (1) all patients with AF have impaired CFR (&#x003C;2.5) even in the absence of obstructive epicardial coronary disease, indicative of CMD; (2) a large proportion of the studied vessels (83&#x0025;) showed discordant FFR/CFR with preserved FFR and low CFR; (3) 47&#x0025; of the coronary arteries in patients with AF and non-obstructive epicardial coronary disease presented structural CMD defined by high HMR (&#x2265;2.5&#x2005;mmHg/cm/s), with a correspondingly high BMR and an impaired response to adenosine, possibly interfering with the FFR assessment; conversely, vessels from patients with AF and non-obstructive epicardial coronary disease with functional CMD (HMR&#x2009;&#x003C;&#x2009;2.5&#x2005;mmHg/cm/s) showed higher bAPV, which could explain the reduced CFR in this subpopulation; (4) the permanent AF subpopulation presented increased values of HMR and BMR compared to persistent AF, while high HMR (&#x2265;2.5&#x2005;mmHg/cm/s) was more often associated with persistent symptoms at 3 months, taking into account the limited sample size of our study.</p>
<sec id="s4a"><title>CFR in patients with AF</title>
<p>All patients with AF in our study presented with diminished CFR (&#x003C;2.5), even in the absence of obstructive coronary artery disease, indicative of CMD. There are multiple studies showing that myocardial ischemia follows more closely changes in coronary blood flow than coronary perfusion pressure (<xref ref-type="bibr" rid="B21">21</xref>, <xref ref-type="bibr" rid="B22">22</xref>). Furthermore, low CFR values (&#x003C;2.5), as observed in the current study, were associated with an excess of major adverse cardiovascular events (MACE) and target vessel failure at 5-year follow-up (<xref ref-type="bibr" rid="B17">17</xref>). Our findings of abnormal CFR in patients with AF are consistent with previous reports of decreased hyperaemic myocardial blood flow in AF assessed by non-invasive methods (<xref ref-type="bibr" rid="B6">6</xref>&#x2013;<xref ref-type="bibr" rid="B9">9</xref>). In addition, Kochiadakis et al. demonstrated diminished CFR in acute experimentally-induced AF in subjects with normal angiographic coronary arteries by means of invasive coronary physiology assessment (<xref ref-type="bibr" rid="B10">10</xref>). This has been postulated to occur due to the irregular ventricular rhythm associated with AF. It took close to twenty years after this initial investigation for a more recent study to revisit the evaluation of CFR in AF using invasive coronary assessment. In this study, Ozcan et al. showed lower CFR values in patients with AF and non-obstructive coronary artery disease, hypothesised to second the presence of microvascular dysfunction, however without evaluating specifically the microcirculation (<xref ref-type="bibr" rid="B11">11</xref>). The observed low CFR in these patients could be partly due to the highly prevalent association of AF with heart failure (<xref ref-type="bibr" rid="B23">23</xref>), or it could be a purveyor of arrhythmia-induced cardiomyopathy. Furthermore, we observed a mean value of CFR of 1.74 in patients with AF and non-obstructive coronary artery disease, which is similar to that observed by Ozcan et al. (1.70) (<xref ref-type="bibr" rid="B11">11</xref>), however lower than that obtained by Kochiadakis et al. (2.15) (<xref ref-type="bibr" rid="B10">10</xref>). Although all three studies suggest the presence of CMD in AF as assessed by CFR (&#x003C;2.5), the higher mean values obtained in the latter study could be explained by CFR measurements performed in acutely-induced AF (<xref ref-type="bibr" rid="B10">10</xref>).</p>
</sec>
<sec id="s4b"><title>Distribution of coronary pressure- and flow-based indices in patients with AF</title>
<p>Interestingly, we could observe a highly prevalent discordance between CFR and FFR (FFR&#x2009;&#x003E;&#x2009;0.8 and CFR&#x2009;&#x003C;&#x2009;2.5) in 83&#x0025; of patients. In the general population, this particular discordance of FFR/CFR was observed in approximately 25&#x0025; of patients according to recent studies (<xref ref-type="bibr" rid="B24">24</xref>, <xref ref-type="bibr" rid="B25">25</xref>), although a previous study reported this discordant population in as low as 6.4&#x0025; of cases (<xref ref-type="bibr" rid="B26">26</xref>). Patients with discordant FFR/CFR presented higher MACE rates than the concordant normal FFR/CFR group at 1 year (<xref ref-type="bibr" rid="B27">27</xref>) and 10 years (<xref ref-type="bibr" rid="B26">26</xref>) follow-up. Nonetheless, regardless of the high rate of discordance of FFR/CFR in terms of their established cut-offs, we could demonstrate a significant, albeit moderate correlation between the absolute FFR and CFR values in patients with AF, similar as reported in the general population (<xref ref-type="bibr" rid="B28">28</xref>).</p>
<p>HSR was found to have superior diagnostic accuracy compared to FFR and CFR when confronted to non-invasive imaging using single photon emission computed tomography (<xref ref-type="bibr" rid="B18">18</xref>), and has been used for evaluating the accuracy of pressure-based indices in the general population (<xref ref-type="bibr" rid="B29">29</xref>, <xref ref-type="bibr" rid="B30">30</xref>). In the current study, we observed that 83&#x0025; of patients showed a concordance of FFR and HSR, using a cut-off for HSR of 0.8&#x2005;mmHg/cm (<xref ref-type="bibr" rid="B18">18</xref>). This is consistent with the previously reported diagnostic agreement between FFR and HSR in the general population of 78.7&#x0025; (<xref ref-type="bibr" rid="B30">30</xref>). However, HSR is also dependent on an adequate hyperaemic response, and can be confounded by the presence of microvascular dysfunction (<xref ref-type="bibr" rid="B13">13</xref>). Previously, Kochiadakis et al. indicated that irregularities in ventricular rhythm may be responsible of diminished CFR in AF (<xref ref-type="bibr" rid="B10">10</xref>), while a recent case report by Mills et al. highlighted that changes in cardiac rhythm associated with AF may impact coronary physiological assessment (<xref ref-type="bibr" rid="B31">31</xref>). In a retrospective setting, we observed that FFR was more robust than instantaneous wave-free ratio (iFR), a resting coronary pressure index, in evaluating coronary lesions in AF, showing similar variability, reproducibility, and lesion classification as observed in patients with sinus rhythm (<xref ref-type="bibr" rid="B32">32</xref>). In addition, adenosine-induced hyperaemia during FFR measurement was found to be equivalent in AF compared to sinus rhythm in terms of magnitude and duration (<xref ref-type="bibr" rid="B33">33</xref>). On the other hand, iFR presented poorer reproducibility in lesion classification in AF, and was prone to increased beat-to-beat variability which correlated with the heart rate variability (<xref ref-type="bibr" rid="B32">32</xref>), supporting the notion that abnormalities in cardiac rhythm may impact evaluation of coronary physiology using resting physiological indices. Further studies are necessary to provide a better understanding on the impact of cardiac rhythm on coronary physiological assessment in AF.</p>
</sec>
<sec id="s4c"><title>Microvascular dysfunction in AF</title>
<p>The low CFR observed in patients with AF and non-obstructive epicardial coronary disease indicates the presence of CMD in this population (<xref ref-type="bibr" rid="B34">34</xref>). CMD is a result of functional or structural alterations of the endothelium (<xref ref-type="bibr" rid="B35">35</xref>). Mechanistically several pathogenic hypotheses were described including impaired NO-mediated vasodilatation, as a consequence of glycocalyx degradation due to oxidative stress, inflammation or ischemia (<xref ref-type="bibr" rid="B35">35</xref>), triggers which have been described in AF (<xref ref-type="bibr" rid="B36">36</xref>). In addition, CMD was also hypothesized to occur secondary to alterations in coronary flow distribution due to compromised intercellular signal transmission, or to impaired metabolic signalling (<xref ref-type="bibr" rid="B35">35</xref>). Furthermore, structural modification of the microcirculation such as capillary rarefaction and remodelling can contribute to increased coronary microvascular resistance (<xref ref-type="bibr" rid="B37">37</xref>). Previous studies have indicated the presence of microvascular coronary dysfunction in AF (<xref ref-type="bibr" rid="B11">11</xref>). Using positron emission tomography, Range et al. identified increased coronary vascular resistance under hyperaemic conditions in patients with AF (<xref ref-type="bibr" rid="B9">9</xref>). Similarly, Kochiadakis et al. observed increased hyperaemic coronary vascular resistance in subjects with acute experimentally-induced AF compared to sinus rhythm using invasive coronary assessment (<xref ref-type="bibr" rid="B10">10</xref>). The microvascular dysfunction observed in AF could be responsible for the ischemic manifestation (chest pain, increased troponin, ECG modifications) in the absence of significant epicardial coronary disease (<xref ref-type="bibr" rid="B38">38</xref>). In addition, the presence of microvascular disease in the general population was shown to be associated with poorer prognosis in terms of cardiac mortality (<xref ref-type="bibr" rid="B39">39</xref>).</p>
<p>The microvascular coronary status is reflected in terms of coronary indices by HMR and BMR. Recent studies have identified that HMR values above 2.5&#x2005;mmHg/cm/s are suggestive of increased microvascular resistance (<xref ref-type="bibr" rid="B19">19</xref>, <xref ref-type="bibr" rid="B20">20</xref>) defining structural CMD, whereas functional CMD is characterized by HMR&#x2009;&#x003C;&#x2009;2.5&#x2005;mmHg/cm/s in presence of diminished CFR (<xref ref-type="bibr" rid="B16">16</xref>, <xref ref-type="bibr" rid="B40">40</xref>). Interestingly, we identified amongst the population with AF and non-obstructive epicardial coronary disease, 47&#x0025; (7/15) vessels showing HMR&#x2009;&#x2265;&#x2009;2.5 mmHg/cm/s, which contrasts to approximately 21&#x0025; reported in the general population (<xref ref-type="bibr" rid="B16">16</xref>). Using this threshold, we divided the patients with AF and non-obstructive epicardial disease as presenting structural CMD (HMR&#x2009;&#x2265;&#x2009;2.5&#x2005;mmHg/cm/s) or functional CMD (HMR&#x2009;&#x003C;&#x2009;2.5&#x2005;mmHg/cm/s), demonstrating different physiological and clinical characteristics. Coronary arteries from patients with AF and structural CMD showed higher BMR values, impaired response to adenosine, lower bAPV and hAPV, and were more frequently associated with permanent AF.</p>
<p>High HMR values were described as a predictor of myocardial ischemia even in the absence of significant epicardial coronary lesions (<xref ref-type="bibr" rid="B14">14</xref>). In addition, high HMR values could influence the evaluation of coronary physiology using pressure-based indices (<xref ref-type="bibr" rid="B41">41</xref>, <xref ref-type="bibr" rid="B42">42</xref>). Specifically in the AF population, a retrospective study found that iFR was less reproducible in assessing intermediate coronary stenoses (<xref ref-type="bibr" rid="B32">32</xref>), that could potentially be explained by the increased microvascular resistance. In addition, in the current study we have observed a strong correlation between FFR and the ratio between HMR and the total vascular resistance (HMR&#x2009;&#x002B;&#x2009;HSR). Previously, we have reported similar hyperaemic responses to adenosine in an overall retrospective population of patients with AF compared to sinus rhythm, however without having available their microvascular resistance characteristics (<xref ref-type="bibr" rid="B33">33</xref>). In the present study, we showed that vessels from patients with AF and high HMR have a reduced hyperaemic response compared to the subgroup of AF and low HMR. Furthermore, we demonstrated that HMR values were inversely correlated with the magnitude of the response to adenosine. This aspect should be considered when assessing epicardial coronary lesion severity using FFR in patients with AF and structural CMD.</p>
<p>Patients with AF and functional CMD present significantly higher bAPV, which could explain the low CFR in this subgroup even in the presence of normal microvascular resistance, as there is a maximum reachable hyperaemia (<xref ref-type="bibr" rid="B43">43</xref>). Previous observations indicate that acute experimentally-induced AF leads to increases in baseline coronary blood flow, that could be partly explained by an increase in heart rate, and hypothesised to be the result of coronary vasodilation secondary to higher metabolic demands in AF (<xref ref-type="bibr" rid="B10">10</xref>). This is in line with our findings that patients with higher bAPV present lower BMR. Another potential explanation of high bAPV reported in the literature was the dysfunction of coronary autoregulation which was associated with adverse long-term outcomes (<xref ref-type="bibr" rid="B39">39</xref>). With increasing AF burden, endothelial dysfunction, sympathetic activation, progressive left ventricular fibrosis and both atrial and ventricular remodelling were described, that could impact irreversibly the coronary microcirculation (<xref ref-type="bibr" rid="B36">36</xref>). Accordingly, patients with AF and high HMR showed increased BMR and impaired response to adenosine, potentially preventing them from reaching maximum hyperaemia.</p>
</sec>
<sec id="s4d"><title>Clinical findings</title>
<p>In our study at 3 months follow-up, patients with AF and non-obstructive epicardial coronary disease presenting with structural CMD demonstrated higher percentage of persistent symptoms, compared to patients with functional CMD. It should be noted that persistent symptoms were solely defined as present or absent, without providing specific quantification of symptom burden. It has been previously hypothesised that the increased microvascular resistance could be responsible for the symptoms suggestive of myocardial ischemia in AF even in the absence of significant coronary artery disease (<xref ref-type="bibr" rid="B36">36</xref>). Our findings seem to support this hypothesis, as we observed more persistent symptoms in patients with AF and increased microvascular resistance in the absence of obstructive coronary artery disease as assessed by FFR. Nevertheless, given the higher prevalence of persistent symptoms in the subpopulation of AF with increased HMR, and the strong correlation between FFR and the microvascular component of the total vascular resistance, possibly a part of the FFR/CFR discordance observed in patients with AF is related to an underestimation of coronary artery stenosis assessed by FFR. Indeed, in our study, solely 17&#x0025; (3/18) vessels were found to have pathologic FFR (&#x2264;0.8), and thus requiring revascularization, which is in contrast with the general population estimates of about 45&#x0025;&#x2013;50&#x0025; (<xref ref-type="bibr" rid="B44">44</xref>, <xref ref-type="bibr" rid="B45">45</xref>). Future studies will be important to address this hypothesis. Interestingly, performing coronary angioplasty in cases of FFR negative lesions, but showing high HMR, has been described in literature as an efficient rescue therapy in case of persistent symptoms (<xref ref-type="bibr" rid="B42">42</xref>). Alternatively, the difference in clinical outcome may also be explained by the presence of predominantly permanent AF in the subgroup with structural CMD, and more prevalent persistent AF in the subgroup with functional CMD. Notably, only 2 out of the 7 patients with functional CMD and absence of persistent symptoms were in sinus rhythm at 3 months clinical follow-up.</p>
<p>Furthermore, as indicated above, it is the subpopulation of permanent AF which presents increased HMR and BMR compared to persistent AF. As such, particular attention is warranted clinically in interpreting the coronary pressure-based indices in this subgroup. Interestingly, in this study, 7 out of the 8 patients with permanent AF experienced AF for a duration of at least 1 year, while 4 out of the 6 patients with persistent AF presented <italic>de novo</italic> AF. This difference in the duration of AF between the two groups could perhaps impact the observed changes in microcirculation characteristics. This could mirror the observed bimodal pattern of coronary microvascular dysfunction (functional CMD, followed by structural CMD) described in diabetes mellitus in a time-dependent manner (<xref ref-type="bibr" rid="B40">40</xref>), and more recently in the general population (<xref ref-type="bibr" rid="B16">16</xref>).</p>
</sec>
<sec id="s4e"><title>Study limitations</title>
<p>We acknowledge that the present study has limitations, including the small sample size, especially regarding the clinical findings, driven by the current shortage of commercial ComboWire&#x00AE; guidewires, the lack of a control group in sinus rhythm, and the limited clinical follow-up, as it was designed firstly as a physiological single-centre study. In addition, the clinical evaluation included only the presence or absence of persistent symptoms, without providing specific quantification of symptom burden. Furthermore, our observations cannot be extrapolated to patients with paroxysmal AF, as they were not included in the study population.</p>
</sec>
</sec>
<sec id="s5" sec-type="conclusions"><title>Conclusion</title>
<p>This is the first study characterising the coronary physiology in a real-life AF population using simultaneous assessment of pressure- and coronary flow- indices. We demonstrate that all studied vessels from patients with AF and non-obstructive epicardial coronary disease have impaired CFR (&#x003C;2.5) indicative of CMD, and we identified an increased prevalence of structural CMD (HMR&#x2009;&#x2265;&#x2009;2.5&#x2005;mmHg/cm/s) compared to the general population. Vessels from patients with AF and structural CMD showed reduced hyperaemic responses to adenosine, possibly interfering with the FFR assessment. In addition, we found that permanent AF presented increased HMR and BMR compared to persistent AF.</p>
</sec>
</body>
<back>
<sec id="s6" sec-type="data-availability"><title>Data availability statement</title>
<p>The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.</p>
</sec>
<sec id="s7" sec-type="ethics-statement"><title>Ethics statement</title>
<p>The studies involving humans were approved by the Ethical Committee of CHU Brugmann (reference number CE 2020/17). The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.</p>
</sec>
<sec id="s8" sec-type="author-contributions"><title>Author contributions</title>
<p>GP and JC: designed the study and the methodology. GP, BB, SS, MM, and JC: collected the data. GP, PB, and JC: analysed and interpreted the data. GP: wrote the manuscript. GP, BB, SS, MM, PB, and JC: discussed the results and provided feedback on the manuscript. All authors contributed to the article and approved the submitted version.</p>
</sec>
<sec id="s9" sec-type="COI-statement"><title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="s11" sec-type="funding-information"><title>Funding</title>
<p>This study was supported by a grant from The Fund for Cardiac Surgery, Belgium.</p>
</sec>
<sec id="s10" sec-type="disclaimer"><title>Publisher&#x0027;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ref-list><title>References</title>
<ref id="B1"><label>1.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McManus</surname><given-names>DD</given-names></name><name><surname>Rienstra</surname><given-names>M</given-names></name><name><surname>Benjamin</surname><given-names>EJ</given-names></name></person-group>. <article-title>An update on the prognosis of patients with atrial fibrillation</article-title>. <source>Circulation</source>. (<year>2012</year>) <volume>126</volume>(<issue>10</issue>):<fpage>e143</fpage>&#x2013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.112.129759</pub-id><pub-id pub-id-type="pmid">22949543</pub-id></citation></ref>
<ref id="B2"><label>2.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stewart</surname><given-names>S</given-names></name><name><surname>Hart</surname><given-names>CL</given-names></name><name><surname>Hole</surname><given-names>DJ</given-names></name><name><surname>McMurray</surname><given-names>JJ</given-names></name></person-group>. <article-title>A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the renfrew/paisley study</article-title>. <source>Am J Med</source>. (<year>2002</year>) <volume>113</volume>(<issue>5</issue>):<fpage>359</fpage>&#x2013;<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1016/s0002-9343(02)01236-6</pub-id><pub-id pub-id-type="pmid">12401529</pub-id></citation></ref>
<ref id="B3"><label>3.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ruiz-Nodar</surname><given-names>JM</given-names></name><name><surname>Marin</surname><given-names>F</given-names></name><name><surname>Hurtado</surname><given-names>JA</given-names></name><name><surname>Valencia</surname><given-names>J</given-names></name><name><surname>Pinar</surname><given-names>E</given-names></name><name><surname>Pineda</surname><given-names>J</given-names></name><etal/></person-group> <article-title>Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis</article-title>. <source>J Am Coll Cardiol</source>. (<year>2008</year>) <volume>51</volume>(<issue>8</issue>):<fpage>818</fpage>&#x2013;<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1016/j.jacc.2007.11.035</pub-id><pub-id pub-id-type="pmid">18294566</pub-id></citation></ref>
<ref id="B4"><label>4.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lamberts</surname><given-names>M</given-names></name><name><surname>Olesen</surname><given-names>JB</given-names></name><name><surname>Ruwald</surname><given-names>MH</given-names></name><name><surname>Hansen</surname><given-names>CM</given-names></name><name><surname>Karasoy</surname><given-names>D</given-names></name><name><surname>Kristensen</surname><given-names>SL</given-names></name><etal/></person-group> <article-title>Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study</article-title>. <source>Circulation</source>. (<year>2012</year>) <volume>126</volume>(<issue>10</issue>):<fpage>1185</fpage>&#x2013;<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.112.114967</pub-id><pub-id pub-id-type="pmid">22869839</pub-id></citation></ref>
<ref id="B5"><label>5.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Soliman</surname><given-names>EZ</given-names></name><name><surname>Safford</surname><given-names>MM</given-names></name><name><surname>Muntner</surname><given-names>P</given-names></name><name><surname>Khodneva</surname><given-names>Y</given-names></name><name><surname>Dawood</surname><given-names>FZ</given-names></name><name><surname>Zakai</surname><given-names>NA</given-names></name><etal/></person-group> <article-title>Atrial fibrillation and the risk of myocardial infarction</article-title>. <source>JAMA Intern Med</source>. (<year>2014</year>) <volume>174</volume>(<issue>1</issue>):<fpage>107</fpage>&#x2013;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1001/jamainternmed.2013.11912</pub-id><pub-id pub-id-type="pmid">24190540</pub-id></citation></ref>
<ref id="B6"><label>6.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Byrne</surname><given-names>C</given-names></name><name><surname>Hasbak</surname><given-names>P</given-names></name><name><surname>Kjaer</surname><given-names>A</given-names></name><name><surname>Thune</surname><given-names>JJ</given-names></name><name><surname>Kober</surname><given-names>L</given-names></name></person-group>. <article-title>Myocardial perfusion during atrial fibrillation in patients with non-ischaemic systolic heart failure: a cross-sectional study using rubidium-82 positron emission tomography/computed tomography</article-title>. <source>Eur Heart J Cardiovasc Imaging</source>. (<year>2019</year>) <volume>20</volume>(<issue>2</issue>):<fpage>233</fpage>&#x2013;<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1093/ehjci/jey089</pub-id><pub-id pub-id-type="pmid">29992262</pub-id></citation></ref>
<ref id="B7"><label>7.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wijesurendra</surname><given-names>RS</given-names></name><name><surname>Liu</surname><given-names>A</given-names></name><name><surname>Notaristefano</surname><given-names>F</given-names></name><name><surname>Ntusi</surname><given-names>NA</given-names></name><name><surname>Karamitsos</surname><given-names>TD</given-names></name><name><surname>Bashir</surname><given-names>Y</given-names></name><etal/></person-group> <article-title>Myocardial perfusion is impaired and relates to cardiac dysfunction in patients with atrial fibrillation both before and after successful catheter ablation</article-title>. <source>J Am Heart Assoc</source>. (<year>2018</year>) <volume>7</volume>(<issue>15</issue>):<fpage>e009218</fpage>. <pub-id pub-id-type="doi">10.1161/JAHA.118.009218</pub-id><pub-id pub-id-type="pmid">30371239</pub-id></citation></ref>
<ref id="B8"><label>8.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sugimoto</surname><given-names>Y</given-names></name><name><surname>Kato</surname><given-names>S</given-names></name><name><surname>Fukui</surname><given-names>K</given-names></name><name><surname>Iwasawa</surname><given-names>T</given-names></name><name><surname>Utsunomiya</surname><given-names>D</given-names></name><name><surname>Kimura</surname><given-names>K</given-names></name><etal/></person-group> <article-title>Impaired coronary flow reserve evaluated by phase-contrast cine magnetic resonance imaging in patients with atrial fibrillations</article-title>. <source>Heart Vessels</source>. (<year>2021</year>) <volume>36</volume>(<issue>6</issue>):<fpage>775</fpage>&#x2013;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1007/s00380-020-01759-x</pub-id><pub-id pub-id-type="pmid">33484290</pub-id></citation></ref>
<ref id="B9"><label>9.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Range</surname><given-names>FT</given-names></name><name><surname>Schafers</surname><given-names>M</given-names></name><name><surname>Acil</surname><given-names>T</given-names></name><name><surname>Schafers</surname><given-names>KP</given-names></name><name><surname>Kies</surname><given-names>P</given-names></name><name><surname>Paul</surname><given-names>M</given-names></name><etal/></person-group> <article-title>Impaired myocardial perfusion and perfusion reserve associated with increased coronary resistance in persistent idiopathic atrial fibrillation</article-title>. <source>Eur Heart J</source>. (<year>2007</year>) <volume>28</volume>(<issue>18</issue>):<fpage>2223</fpage>&#x2013;<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1093/eurheartj/ehm246</pub-id><pub-id pub-id-type="pmid">17604290</pub-id></citation></ref>
<ref id="B10"><label>10.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kochiadakis</surname><given-names>GE</given-names></name><name><surname>Skalidis</surname><given-names>EI</given-names></name><name><surname>Kalebubas</surname><given-names>MD</given-names></name><name><surname>Igoumenidis</surname><given-names>NE</given-names></name><name><surname>Chrysostomakis</surname><given-names>SI</given-names></name><name><surname>Kanoupakis</surname><given-names>EM</given-names></name><etal/></person-group> <article-title>Effect of acute atrial fibrillation on phasic coronary blood flow pattern and flow reserve in humans</article-title>. <source>Eur Heart J</source>. (<year>2002</year>) <volume>23</volume>(<issue>9</issue>):<fpage>734</fpage>&#x2013;<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1053/euhj.2001.2894</pub-id><pub-id pub-id-type="pmid">11978000</pub-id></citation></ref>
<ref id="B11"><label>11.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ozcan</surname><given-names>C</given-names></name><name><surname>Allan</surname><given-names>T</given-names></name><name><surname>Besser</surname><given-names>SA</given-names></name><name><surname>de la Pena</surname><given-names>A</given-names></name><name><surname>Blair</surname><given-names>J</given-names></name></person-group>. <article-title>The relationship between coronary microvascular dysfunction, atrial fibrillation and heart failure with preserved ejection fraction</article-title>. <source>Am J Cardiovasc Dis</source>. (<year>2021</year>) <volume>11</volume>(<issue>1</issue>):<fpage>29</fpage>&#x2013;<lpage>38</lpage>. <pub-id pub-id-type="pmid">33815917</pub-id>.<pub-id pub-id-type="pmid">33815917</pub-id></citation></ref>
<ref id="B12"><label>12.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hindricks</surname><given-names>G</given-names></name><name><surname>Potpara</surname><given-names>T</given-names></name><name><surname>Dagres</surname><given-names>N</given-names></name><name><surname>Arbelo</surname><given-names>E</given-names></name><name><surname>Bax</surname><given-names>JJ</given-names></name><name><surname>Blomstrom-Lundqvist</surname><given-names>C</given-names></name><etal/></person-group> <article-title>2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European association for cardio-thoracic surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European society of cardiology (ESC) developed with the special contribution of the European heart rhythm association (EHRA) of the ESC</article-title>. <source>Eur Heart J</source>. (<year>2021</year>) <volume>42</volume>(<issue>5</issue>):<fpage>373</fpage>&#x2013;<lpage>498</lpage>. <pub-id pub-id-type="doi">10.1093/eurheartj/ehaa612</pub-id><pub-id pub-id-type="pmid">32860505</pub-id></citation></ref>
<ref id="B13"><label>13.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Al-Obaidi</surname><given-names>FR</given-names></name><name><surname>Fearon</surname><given-names>WF</given-names></name><name><surname>Yong</surname><given-names>ASC</given-names></name></person-group>. <article-title>Invasive physiological indices to determine the functional significance of coronary stenosis</article-title>. <source>Int J Cardiol Heart Vasc</source>. (<year>2018</year>) <volume>18</volume>:<fpage>39</fpage>&#x2013;<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijcha.2018.02.003</pub-id><pub-id pub-id-type="pmid">29876502</pub-id></citation></ref>
<ref id="B14"><label>14.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nolte</surname><given-names>F</given-names></name><name><surname>van de Hoef</surname><given-names>TP</given-names></name><name><surname>Meuwissen</surname><given-names>M</given-names></name><name><surname>Voskuil</surname><given-names>M</given-names></name><name><surname>Chamuleau</surname><given-names>SA</given-names></name><name><surname>Henriques</surname><given-names>JP</given-names></name><etal/></person-group> <article-title>Increased hyperaemic coronary microvascular resistance adds to the presence of myocardial ischaemia</article-title>. <source>EuroIntervention</source>. (<year>2014</year>) <volume>9</volume>(<issue>12</issue>):<fpage>1423</fpage>&#x2013;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.4244/EIJV9I12A240</pub-id><pub-id pub-id-type="pmid">24755383</pub-id></citation></ref>
<ref id="B15"><label>15.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tonino</surname><given-names>PA</given-names></name><name><surname>De Bruyne</surname><given-names>B</given-names></name><name><surname>Pijls</surname><given-names>NH</given-names></name><name><surname>Siebert</surname><given-names>U</given-names></name><name><surname>Ikeno</surname><given-names>F</given-names></name><name><surname>van&#x2019; t Veer</surname><given-names>M</given-names></name><etal/></person-group> <article-title>Fractional flow reserve versus angiography for guiding percutaneous coronary intervention</article-title>. <source>N Engl J Med</source>. (<year>2009</year>) <volume>360</volume>(<issue>3</issue>):<fpage>213</fpage>&#x2013;<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa0807611</pub-id><pub-id pub-id-type="pmid">19144937</pub-id></citation></ref>
<ref id="B16"><label>16.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rahman</surname><given-names>H</given-names></name><name><surname>Demir</surname><given-names>OM</given-names></name><name><surname>Khan</surname><given-names>F</given-names></name><name><surname>Ryan</surname><given-names>M</given-names></name><name><surname>Ellis</surname><given-names>H</given-names></name><name><surname>Mills</surname><given-names>MT</given-names></name><etal/></person-group> <article-title>Physiological stratification of patients with angina due to coronary microvascular dysfunction</article-title>. <source>J Am Coll Cardiol</source>. (<year>2020</year>) <volume>75</volume>(<issue>20</issue>):<fpage>2538</fpage>&#x2013;<lpage>49</lpage>. <pub-id pub-id-type="doi">10.1016/j.jacc.2020.03.051</pub-id><pub-id pub-id-type="pmid">32439003</pub-id></citation></ref>
<ref id="B17"><label>17.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Boerhout</surname><given-names>CKM</given-names></name><name><surname>de Waard</surname><given-names>GA</given-names></name><name><surname>Lee</surname><given-names>JM</given-names></name><name><surname>Mejia-Renteria</surname><given-names>H</given-names></name><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Jung</surname><given-names>J</given-names></name><etal/></person-group> <article-title>Prognostic value of structural and functional coronary microvascular dysfunction in patients with non-obstructive coronary artery disease; from the multicentre international ILIAS registry</article-title>. <source>EuroIntervention</source>. (<year>2022</year>) <volume>18</volume>(<issue>9</issue>):<fpage>719</fpage>&#x2013;<lpage>28</lpage>. <pub-id pub-id-type="doi">10.4244/EIJ-D-22-00043</pub-id><pub-id pub-id-type="pmid">35694826</pub-id></citation></ref>
<ref id="B18"><label>18.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Meuwissen</surname><given-names>M</given-names></name><name><surname>Siebes</surname><given-names>M</given-names></name><name><surname>Chamuleau</surname><given-names>SA</given-names></name><name><surname>van Eck-Smit</surname><given-names>BL</given-names></name><name><surname>Koch</surname><given-names>KT</given-names></name><name><surname>de Winter</surname><given-names>RJ</given-names></name><etal/></person-group> <article-title>Hyperemic stenosis resistance index for evaluation of functional coronary lesion severity</article-title>. <source>Circulation</source>. (<year>2002</year>) <volume>106</volume>(<issue>4</issue>):<fpage>441</fpage>&#x2013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1161/01.cir.0000023041.26199.29</pub-id><pub-id pub-id-type="pmid">12135943</pub-id></citation></ref>
<ref id="B19"><label>19.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>RP</given-names></name><name><surname>de Waard</surname><given-names>GA</given-names></name><name><surname>De Silva</surname><given-names>K</given-names></name><name><surname>Lumley</surname><given-names>M</given-names></name><name><surname>Asrress</surname><given-names>K</given-names></name><name><surname>Arri</surname><given-names>S</given-names></name><etal/></person-group> <article-title>Doppler versus thermodilution-derived coronary microvascular resistance to predict coronary microvascular dysfunction in patients with acute myocardial infarction or stable angina pectoris</article-title>. <source>Am J Cardiol</source>. (<year>2018</year>) <volume>121</volume>(<issue>1</issue>):<fpage>1</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.amjcard.2017.09.012</pub-id><pub-id pub-id-type="pmid">29132649</pub-id></citation></ref>
<ref id="B20"><label>20.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Feenstra</surname><given-names>RGT</given-names></name><name><surname>Seitz</surname><given-names>A</given-names></name><name><surname>Boerhout</surname><given-names>CKM</given-names></name><name><surname>de Winter</surname><given-names>RJ</given-names></name><name><surname>Ong</surname><given-names>P</given-names></name><name><surname>Beijk</surname><given-names>MAM</given-names></name><etal/></person-group> <article-title>Reference values for intracoronary Doppler flow velocity-derived hyperaemic microvascular resistance index</article-title>. <source>Int J Cardiol</source>. (<year>2023</year>) <volume>371</volume>:<fpage>16</fpage>&#x2013;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijcard.2022.09.054</pub-id></citation></ref>
<ref id="B21"><label>21.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>NP</given-names></name><name><surname>Gould</surname><given-names>KL</given-names></name></person-group>. <article-title>Physiological basis for angina and ST-segment change PET-verified thresholds of quantitative stress myocardial perfusion and coronary flow reserve</article-title>. <source>JACC Cardiovasc Imaging</source>. (<year>2011</year>) <volume>4</volume>(<issue>9</issue>):<fpage>990</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.jcmg.2011.06.015</pub-id><pub-id pub-id-type="pmid">21920337</pub-id></citation></ref>
<ref id="B22"><label>22.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>NP</given-names></name><name><surname>Gould</surname><given-names>KL</given-names></name></person-group>. <article-title>Integrating noninvasive absolute flow, coronary flow reserve, and ischemic thresholds into a comprehensive map of physiological severity</article-title>. <source>JACC Cardiovasc Imaging</source>. (<year>2012</year>) <volume>5</volume>(<issue>4</issue>):<fpage>430</fpage>&#x2013;<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1016/j.jcmg.2011.12.014</pub-id><pub-id pub-id-type="pmid">22498334</pub-id></citation></ref>
<ref id="B23"><label>23.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Maisel</surname><given-names>WH</given-names></name><name><surname>Stevenson</surname><given-names>LW</given-names></name></person-group>. <article-title>Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy</article-title>. <source>Am J Cardiol</source>. (<year>2003</year>) <volume>91</volume>(<issue>6A</issue>):<fpage>2D</fpage>&#x2013;<lpage>8D</lpage>. <pub-id pub-id-type="doi">10.1016/s0002-9149(02)03373-8</pub-id><pub-id pub-id-type="pmid">12670636</pub-id></citation></ref>
<ref id="B24"><label>24.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ahn</surname><given-names>SG</given-names></name><name><surname>Suh</surname><given-names>J</given-names></name><name><surname>Hung</surname><given-names>OY</given-names></name><name><surname>Lee</surname><given-names>HS</given-names></name><name><surname>Bouchi</surname><given-names>YH</given-names></name><name><surname>Zeng</surname><given-names>W</given-names></name><etal/></person-group> <article-title>Discordance between fractional flow reserve and coronary flow reserve: insights from intracoronary imaging and physiological assessment</article-title>. <source>JACC Cardiovasc Interv</source>. (<year>2017</year>) <volume>10</volume>(<issue>10</issue>):<fpage>999</fpage>&#x2013;<lpage>1007</lpage>. <pub-id pub-id-type="doi">10.1016/j.jcin.2017.03.006</pub-id><pub-id pub-id-type="pmid">28521932</pub-id></citation></ref>
<ref id="B25"><label>25.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>NP</given-names></name><name><surname>Matsuo</surname><given-names>H</given-names></name><name><surname>Nakayama</surname><given-names>M</given-names></name><name><surname>Eftekhari</surname><given-names>A</given-names></name><name><surname>Kakuta</surname><given-names>T</given-names></name><name><surname>Tanaka</surname><given-names>N</given-names></name><etal/></person-group> <article-title>Combined pressure and flow measurements to guide treatment of coronary stenoses</article-title>. <source>JACC Cardiovasc Interv</source>. (<year>2021</year>) <volume>14</volume>(<issue>17</issue>):<fpage>1904</fpage>&#x2013;<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1016/j.jcin.2021.07.041</pub-id><pub-id pub-id-type="pmid">34503741</pub-id></citation></ref>
<ref id="B26"><label>26.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van de Hoef</surname><given-names>TP</given-names></name><name><surname>van Lavieren</surname><given-names>MA</given-names></name><name><surname>Damman</surname><given-names>P</given-names></name><name><surname>Delewi</surname><given-names>R</given-names></name><name><surname>Piek</surname><given-names>MA</given-names></name><name><surname>Chamuleau</surname><given-names>SAJ</given-names></name><etal/></person-group> <article-title>Physiological basis and long-term clinical outcome of discordance between fractional flow reserve and coronary flow velocity reserve in coronary stenoses of intermediate severity</article-title>. <source>Circ Cardiovasc Interv</source>. (<year>2014</year>) <volume>7</volume>(<issue>3</issue>):<fpage>301</fpage>&#x2013;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCINTERVENTIONS.113.001049</pub-id><pub-id pub-id-type="pmid">24782198</pub-id></citation></ref>
<ref id="B27"><label>27.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Meuwissen</surname><given-names>M</given-names></name><name><surname>Chamuleau</surname><given-names>SAJ</given-names></name><name><surname>Siebes</surname><given-names>M</given-names></name><name><surname>de Winter</surname><given-names>RJ</given-names></name><name><surname>Koch</surname><given-names>KT</given-names></name><name><surname>Dijksman</surname><given-names>LM</given-names></name><etal/></person-group> <article-title>The prognostic value of combined intracoronary pressure and blood flow velocity measurements after deferral of percutaneous coronary intervention</article-title>. <source>Catheter Cardiovasc Interv</source>. (<year>2008</year>) <volume>71</volume>(<issue>3</issue>):<fpage>291</fpage>&#x2013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1002/ccd.21331</pub-id><pub-id pub-id-type="pmid">18288725</pub-id></citation></ref>
<ref id="B28"><label>28.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>NP</given-names></name><name><surname>Kirkeeide</surname><given-names>RL</given-names></name><name><surname>Gould</surname><given-names>KL</given-names></name></person-group>. <article-title>Is discordance of coronary flow reserve and fractional flow reserve due to methodology or clinically relevant coronary pathophysiology?</article-title> <source>JACC Cardiovasc Imaging</source>. (<year>2012</year>) <volume>5</volume>(<issue>2</issue>):<fpage>193</fpage>&#x2013;<lpage>202</lpage>. <pub-id pub-id-type="doi">10.1016/j.jcmg.2011.09.020</pub-id><pub-id pub-id-type="pmid">22340827</pub-id></citation></ref>
<ref id="B29"><label>29.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sen</surname><given-names>S</given-names></name><name><surname>Asrress</surname><given-names>KN</given-names></name><name><surname>Nijjer</surname><given-names>S</given-names></name><name><surname>Petraco</surname><given-names>R</given-names></name><name><surname>Malik</surname><given-names>IS</given-names></name><name><surname>Foale</surname><given-names>RA</given-names></name><etal/></person-group> <article-title>Diagnostic classification of the instantaneous wave-free ratio is equivalent to fractional flow reserve and is not improved with adenosine administration. Results of CLARIFY (classification accuracy of pressure-only ratios against indices using flow study)</article-title>. <source>J Am Coll Cardiol</source>. (<year>2013</year>) <volume>61</volume>(<issue>13</issue>):<fpage>1409</fpage>&#x2013;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1016/j.jacc.2013.01.034</pub-id><pub-id pub-id-type="pmid">23500218</pub-id></citation></ref>
<ref id="B30"><label>30.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Modi</surname><given-names>BN</given-names></name><name><surname>Rahman</surname><given-names>H</given-names></name><name><surname>Kaier</surname><given-names>T</given-names></name><name><surname>Ryan</surname><given-names>M</given-names></name><name><surname>Williams</surname><given-names>R</given-names></name><name><surname>Briceno</surname><given-names>N</given-names></name><etal/></person-group> <article-title>Revisiting the optimal fractional flow reserve and instantaneous wave-free ratio thresholds for predicting the physiological significance of coronary artery disease</article-title>. <source>Circ Cardiovasc Interv</source>. (<year>2018</year>) <volume>11</volume>(<issue>12</issue>):<fpage>e007041</fpage>. <pub-id pub-id-type="doi">10.1161/CIRCINTERVENTIONS.118.007041</pub-id><pub-id pub-id-type="pmid">30562079</pub-id></citation></ref>
<ref id="B31"><label>31.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mills</surname><given-names>MT</given-names></name><name><surname>Kyriacou</surname><given-names>AL</given-names></name><name><surname>Morris</surname><given-names>PD</given-names></name><name><surname>Gunn</surname><given-names>JP</given-names></name></person-group>. <article-title>Coronary physiological assessment in a patient with atrial fibrillation: the importance of rhythm</article-title>. <source>JACC Cardiovasc Interv</source>. (<year>2021</year>) <volume>14</volume>(<issue>15</issue>):<fpage>1731</fpage>&#x2013;<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1016/j.jcin.2021.05.035</pub-id><pub-id pub-id-type="pmid">34353604</pub-id></citation></ref>
<ref id="B32"><label>32.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pintea Bentea</surname><given-names>G</given-names></name><name><surname>Berdaoui</surname><given-names>B</given-names></name><name><surname>Samyn</surname><given-names>S</given-names></name><name><surname>Morissens</surname><given-names>M</given-names></name><name><surname>Rodriguez</surname><given-names>JC</given-names></name></person-group>. <article-title>Reliability of fractional flow reserve and instantaneous wave-free ratio in assessing intermediate coronary stenosis in patients with atrial fibrillation</article-title>. <source>Am J Cardiol</source>. (<year>2022</year>) <volume>162</volume>:<fpage>105</fpage>&#x2013;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1016/j.amjcard.2021.09.028</pub-id><pub-id pub-id-type="pmid">34728064</pub-id></citation></ref>
<ref id="B33"><label>33.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pintea Bentea</surname><given-names>G</given-names></name><name><surname>Berdaoui</surname><given-names>B</given-names></name><name><surname>Samyn</surname><given-names>S</given-names></name><name><surname>Morissens</surname><given-names>M</given-names></name><name><surname>Van de Borne</surname><given-names>P</given-names></name><name><surname>Castro Rodriguez</surname><given-names>J</given-names></name></person-group>. <article-title>Assessment of intracoronary adenosine-induced hyperemia in patients with atrial fibrillation in comparison with patients in Sinus rhythm</article-title>. <source>Cardiology</source>. (<year>2022</year>) <volume>147</volume>(<issue>4</issue>):<fpage>375</fpage>&#x2013;<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1159/000525781</pub-id><pub-id pub-id-type="pmid">35785773</pub-id></citation></ref>
<ref id="B34"><label>34.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Meuwissen</surname><given-names>M</given-names></name><name><surname>Chamuleau</surname><given-names>SA</given-names></name><name><surname>Siebes</surname><given-names>M</given-names></name><name><surname>Schotborgh</surname><given-names>CE</given-names></name><name><surname>Koch</surname><given-names>KT</given-names></name><name><surname>de Winter</surname><given-names>RJ</given-names></name><etal/></person-group> <article-title>Role of variability in microvascular resistance on fractional flow reserve and coronary blood flow velocity reserve in intermediate coronary lesions</article-title>. <source>Circulation</source>. (<year>2001</year>) <volume>103</volume>(<issue>2</issue>):<fpage>184</fpage>&#x2013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1161/01.cir.103.2.184</pub-id></citation></ref>
<ref id="B35"><label>35.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sucato</surname><given-names>V</given-names></name><name><surname>Novo</surname><given-names>G</given-names></name><name><surname>Saladino</surname><given-names>A</given-names></name><name><surname>Evola</surname><given-names>S</given-names></name><name><surname>Galassi</surname><given-names>AR</given-names></name></person-group>. <article-title>Coronary microvascular dysfunction</article-title>. <source>Minerva Cardioangiol</source>. (<year>2020</year>) <volume>68</volume>(<issue>2</issue>):<fpage>153</fpage>&#x2013;<lpage>63</lpage>. <pub-id pub-id-type="doi">10.23736/S0026-4725.20.05070-7</pub-id><pub-id pub-id-type="pmid">32083426</pub-id></citation></ref>
<ref id="B36"><label>36.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wijesurendra</surname><given-names>RS</given-names></name><name><surname>Casadei</surname><given-names>B</given-names></name></person-group>. <article-title>Atrial fibrillation: effects beyond the atrium?</article-title> <source>Cardiovasc Res</source>. (<year>2015</year>) <volume>105</volume>(<issue>3</issue>):<fpage>238</fpage>&#x2013;<lpage>47</lpage>. <pub-id pub-id-type="doi">10.1093/cvr/cvv001</pub-id><pub-id pub-id-type="pmid">25587048</pub-id></citation></ref>
<ref id="B37"><label>37.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sucato</surname><given-names>V</given-names></name><name><surname>Novo</surname><given-names>G</given-names></name><name><surname>Saladino</surname><given-names>A</given-names></name><name><surname>Rubino</surname><given-names>M</given-names></name><name><surname>Caronna</surname><given-names>N</given-names></name><name><surname>Luparelli</surname><given-names>M</given-names></name><etal/></person-group> <article-title>Ischemia in patients with no obstructive coronary artery disease: classification, diagnosis and treatment of coronary microvascular dysfunction</article-title>. <source>Coron Artery Dis</source>. (<year>2020</year>) <volume>31</volume>(<issue>5</issue>):<fpage>472</fpage>&#x2013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1097/MCA.0000000000000855</pub-id><pub-id pub-id-type="pmid">32073418</pub-id></citation></ref>
<ref id="B38"><label>38.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van den Bos</surname><given-names>EJ</given-names></name><name><surname>Constantinescu</surname><given-names>AA</given-names></name><name><surname>van Domburg</surname><given-names>RT</given-names></name><name><surname>Akin</surname><given-names>S</given-names></name><name><surname>Jordaens</surname><given-names>LJ</given-names></name><name><surname>Kofflard</surname><given-names>MJ</given-names></name></person-group>. <article-title>Minor elevations in troponin I are associated with mortality and adverse cardiac events in patients with atrial fibrillation</article-title>. <source>Eur Heart J</source>. (<year>2011</year>) <volume>32</volume>(<issue>5</issue>):<fpage>611</fpage>&#x2013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1093/eurheartj/ehq491</pub-id><pub-id pub-id-type="pmid">21252170</pub-id></citation></ref>
<ref id="B39"><label>39.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van de Hoef</surname><given-names>TP</given-names></name><name><surname>Bax</surname><given-names>M</given-names></name><name><surname>Damman</surname><given-names>P</given-names></name><name><surname>Delewi</surname><given-names>R</given-names></name><name><surname>Hassell</surname><given-names>ME</given-names></name><name><surname>Piek</surname><given-names>MA</given-names></name><etal/></person-group> <article-title>Impaired coronary autoregulation is associated with long-term fatal events in patients with stable coronary artery disease</article-title>. <source>Circ Cardiovasc Interv</source>. (<year>2013</year>) <volume>6</volume>(<issue>4</issue>):<fpage>329</fpage>&#x2013;<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCINTERVENTIONS.113.000378</pub-id><pub-id pub-id-type="pmid">23899871</pub-id></citation></ref>
<ref id="B40"><label>40.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sezer</surname><given-names>M</given-names></name><name><surname>Kocaaga</surname><given-names>M</given-names></name><name><surname>Aslanger</surname><given-names>E</given-names></name><name><surname>Atici</surname><given-names>A</given-names></name><name><surname>Demirkiran</surname><given-names>A</given-names></name><name><surname>Bugra</surname><given-names>Z</given-names></name><etal/></person-group> <article-title>Bimodal pattern of coronary microvascular involvement in diabetes Mellitus</article-title>. <source>J Am Heart Assoc</source>. (<year>2016</year>) <volume>5</volume>(<issue>11</issue>):<fpage>e003995</fpage>. <pub-id pub-id-type="doi">10.1161/JAHA.116.003995</pub-id><pub-id pub-id-type="pmid">27930353</pub-id></citation></ref>
<ref id="B41"><label>41.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van de Hoef</surname><given-names>TP</given-names></name><name><surname>Nolte</surname><given-names>F</given-names></name><name><surname>Echavarria-Pinto</surname><given-names>M</given-names></name><name><surname>van Lavieren</surname><given-names>MA</given-names></name><name><surname>Damman</surname><given-names>P</given-names></name><name><surname>Chamuleau</surname><given-names>SA</given-names></name><etal/></person-group> <article-title>Impact of hyperaemic microvascular resistance on fractional flow reserve measurements in patients with stable coronary artery disease: insights from combined stenosis and microvascular resistance assessment</article-title>. <source>Heart</source>. (<year>2014</year>) <volume>100</volume>(<issue>12</issue>):<fpage>951</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1136/heartjnl-2013-305124</pub-id><pub-id pub-id-type="pmid">24727867</pub-id></citation></ref>
<ref id="B42"><label>42.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van Lavieren</surname><given-names>MA</given-names></name><name><surname>van de Hoef</surname><given-names>TP</given-names></name><name><surname>Sjauw</surname><given-names>KD</given-names></name><name><surname>Piek</surname><given-names>JJ</given-names></name><name><surname>Ferrara</surname><given-names>A</given-names></name><name><surname>De Bruyne</surname><given-names>B</given-names></name><etal/></person-group> <article-title>How should I treat a patient with refractory angina and a single stenosis with normal FFR but abnormal CFR?</article-title> <source>EuroIntervention</source>. (<year>2015</year>) <volume>11</volume>(<issue>1</issue>):<fpage>125</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.4244/EIJV11I1A23</pub-id><pub-id pub-id-type="pmid">25982657</pub-id></citation></ref>
<ref id="B43"><label>43.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Adjedj</surname><given-names>J</given-names></name><name><surname>Toth</surname><given-names>GG</given-names></name><name><surname>Johnson</surname><given-names>NP</given-names></name><name><surname>Pellicano</surname><given-names>M</given-names></name><name><surname>Ferrara</surname><given-names>A</given-names></name><name><surname>Flore</surname><given-names>V</given-names></name><etal/></person-group> <article-title>Intracoronary adenosine: dose-response relationship with hyperemia</article-title>. <source>JACC Cardiovasc Interv</source>. (<year>2015</year>) <volume>8</volume>(<issue>11</issue>):<fpage>1422</fpage>&#x2013;<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1016/j.jcin.2015.04.028</pub-id><pub-id pub-id-type="pmid">26404193</pub-id></citation></ref>
<ref id="B44"><label>44.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Davies</surname><given-names>JE</given-names></name><name><surname>Sen</surname><given-names>S</given-names></name><name><surname>Dehbi</surname><given-names>HM</given-names></name><name><surname>Al-Lamee</surname><given-names>R</given-names></name><name><surname>Petraco</surname><given-names>R</given-names></name><name><surname>Nijjer</surname><given-names>SS</given-names></name><etal/></person-group> <article-title>Use of the instantaneous wave-free ratio or fractional flow reserve in PCI</article-title>. <source>N Engl J Med</source>. (<year>2017</year>) <volume>376</volume>(<issue>19</issue>):<fpage>1824</fpage>&#x2013;<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1700445</pub-id><pub-id pub-id-type="pmid">28317458</pub-id></citation></ref>
<ref id="B45"><label>45.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gotberg</surname><given-names>M</given-names></name><name><surname>Christiansen</surname><given-names>EH</given-names></name><name><surname>Gudmundsdottir</surname><given-names>IJ</given-names></name><name><surname>Sandhall</surname><given-names>L</given-names></name><name><surname>Danielewicz</surname><given-names>M</given-names></name><name><surname>Jakobsen</surname><given-names>L</given-names></name><etal/></person-group> <article-title>Instantaneous wave-free ratio versus fractional flow reserve to guide PCI</article-title>. <source>N Engl J Med</source>. (<year>2017</year>) <volume>376</volume>(<issue>19</issue>):<fpage>1813</fpage>&#x2013;<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1616540</pub-id><pub-id pub-id-type="pmid">28317438</pub-id></citation></ref></ref-list>
</back>
</article>